Chloroquine by O'Horo, John C
Chloroquine  
Indications/Dosage
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Labeled
• amebiasis
• malaria
• malaria prophylaxis
Off-Label
• coronavirus disease 2019 (COVID-19) †
• discoid lupus erythematosus †
• severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection
†
† Off-label indication
Per the manufacturer, this drug has been shown to be active against most 
strains of the following microorganisms either in vitro and/or in clinical 
infections:
Entamoeba histolytica, Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, 
Plasmodium vivax. 
NOTE: The safety and effectiveness in treating clinical infections due to organisms with in vitro data 
only have not been established in adequate and well-controlled clinical trials.
This drug may also have activity against the following microorganisms:
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
NOTE: Some organisms may not have been adequately studied during clinical trials; therefore, 
exclusion from this list does not necessarily negate the drug’s activity against the organism.
INVESTIGATIONAL USE: For the treatment of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) infection†, the virus that causes 
coronavirus disease 2019 (COVID-19)†
Oral dosage
• Adults weighing 50 kg or more
Available data are limited and efficacy has not been established. Due to a lack of clinical 
data, the National Institutes of Health (NIH) COVID-19 treatment guidelines do not give 
recommendations for or against the use of chloroquine; however, if used, guidelines 
advise monitoring for adverse events including QT interval prolongation.[65314] 1,000 mg 
(600 mg base) PO on day 1 then 500 mg (300 mg base) PO once daily for 4 to 7 days in 
patients in which enrollment in clinical trials is not feasible is suggested by the FDA in the 
Emergency Use Authorization (EUA) statement.[65171] [65172] 500 mg (300 mg base) PO 
twice daily for 10 days is also being evaluated alone and in combination. Preliminary data 
suggest chloroquine may inhibit the exacerbation of pneumonia, improve lung imaging 
findings, promote virus-negative conversion, and shorten the disease course.[65119]
[65120] [65123] [65124] [65125] [65126] [65148]
• Adults weighing less than 50 kg
Available data are limited, and efficacy has not been established. Due to a lack of clinical 
data, the National Institutes of Health (NIH) COVID-19 treatment guidelines do not give 
recommendations for or against the use of chloroquine; however, if used, guidelines 
advise monitoring for adverse events including QT interval prolongation.[65314] 500 mg 
(300 mg base) PO twice daily for 10 days is being evaluated alone and in combination. 
Preliminary data suggest chloroquine may inhibit the exacerbation of pneumonia, improve 
lung imaging findings, promote virus-negative conversion, and shorten the disease course.
[65119] [65120] [65123] [65124] [65125] [65126] [65148]
• Adolescents weighing 50 kg or more
Available data are limited, and efficacy has not been established. Due to a lack of clinical 
data, the National Institutes of Health (NIH) COVID-19 treatment guidelines do not give 
recommendations for or against the use of chloroquine; however, if used, guidelines 
advise monitoring for adverse events including QT interval prolongation.[65314] 1,000 mg 
(600 mg base) PO on day 1 then 500 mg (300 mg base) PO once daily for 4 to 7 days in 
patients in which enrollment in clinical trials is not feasible is suggested by the FDA in the 
Emergency Use Authorization (EUA) statement.[65171] [65172] Based on extrapolation 
from pediatric dosing for other indications and comparative doses to the adult dosing 
regimen suggested for COVID-19, 8.3 mg (5 mg base)/kg/dose PO twice daily [Max: 500 
mg/dose (300 mg base/dose)] is being used in limited pediatric dosing protocols.[29758]
[63245] [65159] A 10-day course is being used in adult patients.[65125] [65126] [65148]
• Adolescents weighing less than 50 kg
Efficacy and optimal dosing in pediatric patients are not established. Due to a lack of 
clinical data, the National Institutes of Health (NIH) COVID-19 treatment guidelines do not 
give recommendations for or against the use of chloroquine; however, if used, guidelines 
advise monitoring for adverse events including QT interval prolongation.[65314] Based on 
extrapolation from pediatric dosing for other indications and comparative doses to the 
adult dosing regimen suggested for COVID-19, 8.3 mg (5 mg base)/kg/dose PO twice 
daily [Max: 500 mg/dose (300 mg base/dose)] is being used in limited pediatric dosing 
protocols.[29758] [63245] [65159] A 10-day course is being used in adult patients.[65125]
[65126] [65148]
• Infants and Children
Efficacy and optimal dosing in pediatric patients are not established. Due to a lack of 
clinical data, the National Institutes of Health (NIH) COVID-19 treatment guidelines do not 
give recommendations for or against the use of chloroquine; however, if used, guidelines 
advise monitoring for adverse events including QT interval prolongation.[65314] Based on 
extrapolation from pediatric dosing for other indications and comparative doses to the 
adult dosing regimen suggested for COVID-19, 8.3 mg (5 mg base)/kg/dose PO twice 
daily [Max: 500 mg/dose (300 mg base/dose)] is being used in limited pediatric dosing 
protocols.[29758] [63245] [65159] A 10-day course is being used in adult patients.[65125]
[65126] [65148]
For the treatment of uncomplicated malaria due to susceptible strains of 
P. falciparum, P. knowlesi†, P. malariae, P. ovale, and P. vivax
Oral dosage
• Adults
16.6 mg (10 mg base)/kg/dose [Max: 1,000 mg/dose (600 mg base/dose)] PO once, then 
8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO in 6 to 8 hours, 
then 8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO once daily 
for 2 days.[29758] For P. vivax or P. ovale, give in combination with primaquine phosphate 
or tafenoquine. Guidelines recommend chloroquine for uncomplicated malaria in patients 
with chloroquine-sensitive P. falciparum or P. vivax or in all patients with P. malariae, P. 
knowlesi, or P. ovale.[64059]
• Infants, Children, and Adolescents
16.6 mg (10 mg base)/kg/dose [Max: 1,000 mg/dose (600 mg base/dose)] PO once, then 
8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO in 6 to 8 hours, 
then 8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO once daily 
for 2 days.[29758] [63245] For P. vivax or P. ovale, give in combination with primaquine 
phosphate or tafenoquine. Guidelines recommend chloroquine for uncomplicated malaria 
in patients with chloroquine-sensitive P. falciparum or P. vivax or in all patients with P. 
malariae, P. knowlesi, or P. ovale.[64059]
For malaria prophylaxis against chloroquine-sensitive Plasmodium species
Oral dosage
• Adults
500 mg (300 mg base) PO weekly on the same day of each week, starting 2 weeks before 
entering the endemic area and continuing for 8 weeks after leaving the area. If it is not 
feasible to begin therapy before entering the endemic area, use 1,000 mg (600 mg base) 
as initial loading dose given in 2 divided doses 6 hours apart.[29758] Alternatively, 
guidelines suggest a shorter course; start the usual dosage regimen 1 to 2 weeks prior to 
entry into the endemic area and continue for 4 weeks after leaving the area.[63990]
• Pregnant Female Adults†
500 mg (300 mg base) PO weekly for duration of pregnancy for P. ovale or P. vivax
infections after completing acute treatment. After delivery, subsequent treatment with 
primaquine phosphate or tafenoquine is needed in patients without G6PD deficiency.
[64059]
• Pregnant Female Adolescents†
500 mg (300 mg base) PO weekly for duration of pregnancy for P. ovale or P. vivax
infections after completing acute treatment. After delivery, subsequent treatment with 
primaquine phosphate or tafenoquine (16 years and older) is needed in patients without 
G6PD deficiency.[64059]
• Infants, Children, and Adolescents
8.3 mg (5 mg base)/kg/dose [Max: 500 mg/dose (300 mg base/dose)] PO weekly on the 
same day of each week, starting 2 weeks before entering the endemic area and 
continuing for 8 weeks after leaving the area. If it is not feasible to begin therapy before 
entering the endemic area, use 16.6 mg (10 mg base)/kg/dose [Max: 1,000 mg/dose (600 
mg base/dose)] as initial loading dose given in 2 divided doses 6 hours apart.[29758]
[63245] Alternatively, guidelines suggest a shorter course; start the usual dosage regimen 
1 to 2 weeks prior to entry into the endemic area and continue for 4 weeks after leaving 
the area.[63245] [63990]
For the treatment of extraintestinal amebiasis (adjunct treatment with an 
effective intestinal amebicide)
Oral dosage
• Adults
1,000 mg (600 mg base) PO once daily for 2 days, then 500 mg (300 mg base) PO once 
daily for at least 2 to 3 weeks.[29758]
For the treatment of discoid lupus erythematosus†
Oral dosage
• Adults
125 to 250 mg (75 to 150 mg base) PO once daily. Do not exceed 3.5 to 4 mg/kg/day to 
minimize retinal toxicity. Chloroquine is recommended in patients who fail 
hydroxychloroquine plus quinacrine; quinacrine may be continued with chloroquine.[62154]
Therapeutic Drug Monitoring
The following recommendations are for baseline and continuous monitoring when using 
chloroquine with azithromycin:
• Obtain a pre-treatment QTc using a standard 12-lead ECG, telemetry, or mobile ECG 
device.
• Obtain baseline electrolytes, including calcium, magnesium, and potassium; correct 
abnormalities.
• Determine if the patient is currently on any QT-prolonging medications that can be 
discontinued.[65170]
• Document high-risk cardiovascular and comorbid conditions.[65170] Assess and adjust 
for hepatic and renal dysfunction.[65242]
Inpatient Use
• Place telemetry prior to initiation, if possible.
• Monitor and optimize serum electrolytes daily.[65242]
• If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to 
develop an exaggerated QTc response (i.e., change of 60 msec or more), correct 
contributing electrolyte abnormalities, review and discontinue other unnecessary QTc 
prolonging medications, and proceed with close QTc surveillance.[65170] Some experts 
recommend withholding treatment for patients with a baseline QTc of 500 msec or 
more (or more than 530 to 550 msec in patients with a QRS interval more than 120 
msec) or in those with congenital long QT syndrome.[65242]
• If the baseline QTc is 460 to 499 msec (prepubertal), 470 to 499 msec (postpubertal 
males), or 480 to 499 msec (postpubertal females), correct contributing electrolyte 
abnormalities, review and discontinue other unnecessary QTc prolonging medications, 
and obtain an initial on-therapy QTc daily (or 48 and 96 hours after treatment 
initiation).[65170] [65242]
• If the baseline QTc is less than 460 msec (prepubertal), less than 470 msec 
(postpubertal males), or less than 480 msec (postpubertal females), correct electrolyte 
abnormalities and obtain an initial on-therapy QTc daily (or 48 and 96 hours after 
treatment initiation).[65170] [65242]
• Obtain an initial on-therapy QTc approximately 2 to 4 hours after the first dose and 
then daily (some recommend 48 and 96 hours after treatment initiation).[65170] [65242]
• Discontinue azithromycin and/or reduce the antimalarial dose if the subsequent QTc is 
prolonged or significantly increased above the specified parameters. If the QTc remains 
prolonged or significantly increased, reevaluate the risk/benefit of therapy, consider 
consultation with an electrophysiologist, and consider hydroxychloroquine/chloroquine 
discontinuation.[65242]
Outpatient Use
• Do not initiate outpatient therapy in the setting of acute renal or hepatic failure.[65242]
• If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to 
develop an exaggerated QTc response (i.e., change of 60 msec or more), correct 
contributing electrolyte abnormalities, review and discontinue other unnecessary QTc 
prolonging medications, and proceed with close QTc surveillance.[65170] Some experts 
recommend withholding treatment in patients with a baseline QTc of 480 msec or more 
(or more than 510 to 530 msec in patients with a QRS interval more than 120 msec), 
congenital long QT syndrome, or a Tisdale risk score of 11 or more.[65242]
• Consider no further ECG/telemetry assessment for patients with a Tisdale risk score of 
6 or less, if resource or quarantine constraints are prohibitive of monitoring. Otherwise, 
repeat the ECT 2 to 3 hours after dosing on day 3 of therapy. If the QTc exceeds 500 
msec (or 530 to 550 msec if QRS is more than 120 msec) or increases by more than 30 
to 60 msec, consider discontinuing therapy.[65242]
Maximum Dosage Limits
• Adults 
1,000 mg/dose (600 mg base/dose) PO for malaria up to a total of 2.5 g (1.5 g base) PO 
in 48 hours; 500 mg/week (300 mg base/week) PO for malaria prophylaxis; 1,000 
mg/day (600 mg base/day) PO for other indications.
• Geriatric 
1,000 mg/dose (600 mg base/dose) PO for malaria up to a total of 2.5 g (1.5 g base) PO 
in 48 hours; 500 mg/week (300 mg base/week) PO for malaria prophylaxis; 1,000 
mg/day (600 mg base/day) PO for other indications.
• Adolescents 
16.6 mg/kg/dose (10 mg base/kg/dose) [Max: 1,000 mg (600 mg base)] PO for malaria 
up to a total of 41.5 mg/kg (25 mg/kg base) [Max: 2.5 g (1.5 g base)] PO in 48 hours; 
8.3 mg/kg/week (5 mg base/kg/week) [Max: 500 mg/week (300 mg base/week)] PO 
for malaria prophylaxis.
• Children 
16.6 mg/kg/dose (10 mg base/kg/dose) [Max: 1,000 mg (600 mg base)] PO for malaria 
up to a total of 41.5 mg/kg (25 mg/kg base) [Max: 2.5 g (1.5 g base)] PO in 48 hours; 
8.3 mg/kg/week (5 mg base/kg/week) [Max: 500 mg/week (300 mg base/week)] PO 
for malaria prophylaxis.
• Infants 
16.6 mg/kg/dose (10 mg base/kg/dose) PO for malaria up to a total of 41.5 mg/kg (25 
mg/kg base) PO in 48 hours; 8.3 mg/kg/week (5 mg base/kg/week) PO for malaria 
prophylaxis.
• Neonates 
Safety and efficacy have not been established.
Patients with Hepatic Impairment Dosing
Chloroquine concentrates in the liver. However, no specific dosage adjustment guidelines are 
available for patients with hepatic impairment.[29758]
Patients with Renal Impairment Dosing
CrCl 10 mL/minute or more: No dosage adjustment necessary.
CrCl less than 10 mL/minute: Decrease dose by 50%.[32569]
Intermittent hemodialysis:
Decrease dose by 50%.[32569]
Peritoneal dialysis:
Decrease dose by 50%.[32569]
Continuous renal replacement therapy:
No dosage adjustment necessary.[32569]
† Off-label indication
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How Supplied
Chloroquine Hydrochloride Solution for injection
Aralen 50mg/ml Solution for Injection (00024-0074) (Sanofi U.S. LLC) (off market)
Chloroquine Phosphate Oral tablet
Chloroquine Phosphate 250mg Tablet (00143-1195) (Hikma 
Pharmaceuticals USA inc.) (off market)
Chloroquine Phosphate 250mg Tablet (00143-1195) (Hikma 
Pharmaceuticals USA Inc.) (off market)
Chloroquine Phosphate 250mg Tablet (00115-2790) (Impax Generics, 
a division of Impax Laboratories, Inc.) (off market)
Chloroquine Phosphate Oral tablet
Chloroquine Phosphate 250mg Tablet (00115-7056) (Impax Generics, a division of Impax Laboratories, Inc.) (off 
market)
Chloroquine Phosphate 250mg Tablet (64980-0177) (Rising 
Pharmaceuticals Inc) (off market)
Chloroquine Phosphate 250mg Tablet (64980-0177) (Rising 
Pharmaceuticals Inc) 
Chloroquine Phosphate 250mg Tablet (63304-0460) (Sun 
Pharmaceutical Industries, Inc.) (off market)
Aralen 500mg Tablet (00280-0084) (Bayer Corp Consumer Care Div) (off market)
Aralen 500mg Tablet (00024-0084) (Sanofi U.S. LLC) (off market)
Chloroquine Phosphate 500mg Tablet (00143-2125) (Hikma 
Pharmaceuticals USA Inc.) (off market)
Chloroquine Phosphate 500mg Tablet (00115-7010) (Impax Generics, 
a division of Impax Laboratories, Inc.) (off market)
Chloroquine Phosphate 500mg Tablet (55289-0856) (PD-Rx 
Pharmaceuticals, Inc.) 
Chloroquine Phosphate 500mg Tablet (43063-0454) (PD-Rx Pharmaceuticals, Inc.) 
Chloroquine Phosphate 500mg Tablet (64980-0178) (Rising Pharmaceuticals Inc) (off market)
Chloroquine Phosphate 500mg Tablet (64980-0178) (Rising Pharmaceuticals Inc) 
Chloroquine Phosphate Oral tablet
Chloroquine Phosphate 500mg Tablet (63304-0461) (Sun Pharmaceutical Industries, Inc.) (off market)
Description/Classification
Description
Chloroquine is a 4-aminoquinoline anti-protozoal agent indicated for the treatment and 
prophylaxis of susceptible malaria strains and for the treatment of extraintestinal amebiasis. 
Chloroquine is not active against gametocytes and the exoerythrocytic forms including the 
hypnozoite stage of the Plasmodium parasites. Resistance to chloroquine is widespread. 
Irreversible retinal damage has been observed with use, and postmarketing cases of life-
threatening and fatal cardiomyopathy, including ventricular arrhythmias and torsade de pointes 
(TdP), have been reported.[29758]
Updates for coronavirus disease 2019 (COVID-19):
Available data are limited. Due to a lack of clinical data, the National Institutes of Health (NIH) 
COVID-19 treatment guidelines do not give recommendations for or against the use of 
chloroquine; however, if used, guidelines advise monitoring for adverse events including QT 
interval prolongation.[65314] The FDA has issued an Emergency Use Authorization (EUA) for the 
use of chloroquine to treat COVID-19 patients for whom clinical trial participation is not feasible.
[65171][65172] Preliminary data suggest chloroquine may have clinical benefit in the treatment of 
COVID-19 due to SARS-CoV-2. In results for more than 100 patients, chloroquine was superior 
to control in inhibiting the exacerbation of pneumonia.[65119][65124][65126] Additional data 
regarding clinical efficacy for COVID-19 are being evaluated.[65123]
Classifications
• General Anti-infectives Systemic
◦ Antiparasitic Agents, Insecticides, and Repellants
◾ Antiprotozoals
◾ Agents for Amoebiasis and Other Protozoal Diseases
◾ Antimalarials
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Administration Information
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Route-Specific Administration
Oral Administration
• May administer with meals in patients who experience gastrointestinal side effects.
[63990]
Oral Solid Formulations
• To mitigate bitter tablet taste for children, tablets may be pulverized and enclosed in 
gelatin capsules. If the child is unable to swallow the capsules or tablets, the gelatin 
capsules may be opened and the contents mixed with a small amount of something 
sweet, such as applesauce, chocolate syrup, or jelly.[63990]
Extemporaneous Compounding-Oral
NOTE: Chloroquine extemporaneous suspension is not FDA-approved.
Extemporaneous chloroquine suspension has been compounded using the following formulations:
• Chloroquine phosphate 15 mg/mL in 1:1 Ora-Sweet and Ora-Plus, 1:1 Ora-Sweet SF 
and Ora-Plus, or Cherry Syrup: 
◦ Pulverize three 500-mg chloroquine phosphate tablets into a fine powder in 
a mortar.
◦ Add approximately 15 mL of vehicle, which may be a 1:1 mixture of Ora-
Sweet and Ora-Plus, 1:1 mixture of Ora-Sweet SF and Ora-Plus, or cherry 
syrup.
◦ Add the vehicle in geometric portions almost to volume and mix thoroughly 
after each addition.
◦ Transfer the contents of the mortar to a calibrated bottle.
◦ Add enough vehicle to bring the final volume to 100 mL.
◦ Label "Shake Well Before Using" and "Protect from Light"
◦ Storage: The suspension is stable for 60 days when stored without light at 5 
and 25 degrees C.[62145]
• Chloroquine base 10 mg/mL in Cherry Syrup: 
◦ Pulverize two 500-mg chloroquine phosphate tablets in a mortar after 
removing the film coating.
◦ Levigate with a small amount of sterile water.
◦ Add by geometric proportions a significant amount of cherry syrup, and 
levigate until a uniform mixture is obtained.
◦ Transfer the contents of the mortar to a conical graduated cylinder.
◦ Add enough cherry syrup to bring the final volume to 60 mL.
◦ Pour the suspension into an amber glass bottle and shake vigorously.
◦ Storage: The suspension is stable for up to 4 weeks under refrigeration (4 
degrees C), at room temperature (22 to 25 degrees C), and at 29 degrees C.
[62150]
• Chloroquine base 15 mg/mL in Glycerin or Distilled Water, Cologel (Lilly), and 
Simple Syrup/Cherry Syrup: 
◦ Pulverize two 500-mg chloroquine phosphate tablets in a mortar.
◦ Levigate with a small amount of glycerin or distilled water.
◦ Add 13 mL of Cologel, and levigate until a uniform mixture is obtained.
◦ Add by geometric proportion a significant amount of a 2:1 simple 
syrup/cherry syrup mixture, and levigate until a uniform mixture is 
obtained.
◦ Transfer the contents of the mortar to a conical graduated cylinder.
◦ Add enough of the syrup mixture to bring the final volume to 40 mL.
◦ Pour the suspension into an amber glass bottle and shake vigorously.
◦ Label "Shake Well" and "Refrigerate".
◦ Storage: The suspension is stable for 3 days when stored in the refrigerator.
[62172]
Clinical Pharmaceutics Information
From Trissel's 2™ Clinical Pharmaceutics Database 
Chloroquine
1. pH Range
pH 5.5 to 6.6 (as the hydrochloride salt)
References
McEvoy GK (ed). AHFS Drug Information (current edition). Bethesda, MD: American 
Society of Health-System Pharmacists. 
2. Stability
Chloroquine sulfate in intact containers stored as directed by the manufacturer is stable 
until the labeled expiration date. Infusion Solutions: Chloroquine sulfate 0.5 mg/mL in 
sodium chloride 0.9% was reported by Martens et al. to be stable for 24 hours at 21 
degree C protected from exposure to light.
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Anon. Manufacturer's information and labeling. (Package insert). 
Martens HJ, De Goede PN, van Loenen AC. Sorption of various drugs in polyvinyl 
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3. Light Exposure
Chloroquine injection should be protected from exposure to light during long-term 
storage.
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4. Filtration
Geary et al. reported that chloroquine exhibited binding to cellulose acetate filters. 
About 60% or more of the drug was lost from 10 mL of a chloroquine 0.32-mg/mL 
solution passed through Millipore and Nalgene 0.45-micron cellulose acetate filters. 
No drug loss occurred when the chloroquine solution was passed through a 
polycarbonate filter. The clinical implications, if any, of binding to filters from such a 
low concentration are uncertain.
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5. Sorption Leaching
Geary et al. reported that chloroquine at low concentrations exhibits sorption to glass. 
As much as 30 to 40% was lost to glass test tubes from a 0.32 mg/mL solution. No loss 
due to sorption to polycarbonate, polystyrene, or polypropylene plastics was found. 
The clinical implications, if any, of sorption from such a low concentration are 
uncertain. Moreover, Martens et al. were unable to confirm this result. They found no 
sorption to glass bottles, polyvinyl chloride (PVC) plastic bags, and polyethylene-lined 
laminated bags from a chloroquine 0.5 mg/mL (as sulfate) solution.
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6. Stability Max
Maximum reported stability period: In NS- 24 hours at room temperature
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Compounding Drug Information
From Trissel's 2™ Clinical Pharmaceutics Database 
Chloroquine
1. Identity/Properties
Chloroquine is a white to slightly yellow, odorless crystalline powder with a bitter 
taste. The hydrochloride, a white crystalline substance, is prepared using hydrochloric 
acid. Chloroquine hydrochloride 123 mg is approximately equivalent to 100 mg of 
chloroquine. The phosphate is a white or almost white, odorless, hygroscopic 
crystalline powder with a bitter taste. Chloroquine phosphate 161 mg is approximately 
equivalent to 100 mg of chloroquine. Solubility: Chloroquine is only slightly soluble in 
water. The hydrochloride and the phosphate are freely soluble in water. The phosphate 
has an aqueous solubility of about 250 mg/mL but is almost insoluble in ethanol. pH: 
Chloroquine hydrochloride injection has a pH between 5.5 and 6.5. A 1% chloroquine 
phosphate solution has a pH of about 4.5.
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Anon. The United States Pharmacopeia. Rockville, Maryland: The United States 
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2. General Stability Info
Chloroquine products should be stored in well-closed containers. The injection (as the 
hydrochloride) should be stored at controlled room temperature and protected from 
freezing and temperatures exceeding 40degree C. The phosphate is light sensitive, 
discoloring upon light exposure.
References
Anon. Martindale The Complete Drug Reference. London: The Pharmaceutical Press. 
Current edition and selected information from prior editions. 
Anon. The United States Pharmacopeia. Rockville, Maryland: The United States 
Pharmacopeial Convention. Current edition. 
McEvoy GK (ed). AHFS Drug Information (current edition). Bethesda, MD: American 
Society of Health-System Pharmacists. 
3. Injection, extemporaneous
Injections, like other sterile drugs, should be prepared in a suitable clean air 
environment using appropriate aseptic procedures. When prepared from non-sterile 
components, an appropriate and effective sterilization method must be employed. Allen 
reported on a compounded formulation of chloroquine phosphate 64.5-mg/mL 
injection. The injection had the following formula: Chloroquine phosphate- 6.45 g 
Benzyl alcohol- 2 g Sterile water for injection- qs 100 mL The recommended method 
of preparation is to dissolve the chloroquine phosphate powder in about 90 mL of 
sterile water for injection. The benzyl alcohol is then added and stirred until dissolved. 
Sterile water for injection sufficient to bring the volume to 100 mL is added and the 
solution is mixed well. The solution is to be filtered through a suitable 0.2-micron 
sterilizing filter and packaged in sterile containers. If no sterility test is performed, the 
USP specifies a beyond-use date of 24 hours at room temperature or three days stored 
under refrigeration because of concern for inadvertent microbiological contamination 
during preparation. However, if an official USP sterility test for each batch of drug is 
performed, the author recommended a beyond-use date of six months at room 
temperature because this formula is similar or the same as a commercial medication in 
some countries with an expiration date of two years or more.
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4. Oral Liquid
Study 1: Closson reported that chloroquine hydrochloride injection (Aralen HCl, 
Sanofi Winthrop) was added to simple syrup to make a 20-mg/mL oral pediatric dosage 
form. The product was incubated at 49degree C for 63 hours; no visible changes in 
physical appearance or consistency occurred. The product then was frozen at -6degree 
C for eight hours; it became a white frozen solid and reliquified upon warming to its 
original colorless, slightly hazy appearance. No chemical analysis was performed. 
Study 2: Allen and Erickson evaluated the stability of three chloroquine phosphate 15-
mg/mL oral liquids extemporaneously compounded from tablets. Vehicles used in this 
study were (1) an equal parts mixture of Ora-Sweet and Ora-Plus (Paddock), (2) an 
equal parts mixture of Ora-Sweet SF and Ora-Plus (Paddock), and (3) cherry syrup 
(Robinson Laboratories) mixed 1:4 with simple syrup. Three chloroquine phosphate 
500-mg tablets (Sanofi Winthrop) were crushed and comminuted to fine powder using 
a mortar and pestle. About 15 mL of the test vehicle was added to the powder and 
mixed to yield a uniform paste. Additional vehicle was added geo-metrically and 
brought to the final volume of 100 mL, mixing thoroughly after each addition. The 
process was repeated for each of the three test suspension vehicles. Samples of each of 
the finished suspensions were packaged in 120-mL amber poly-ethylene terephthalate 
plastic prescription bottles and stored at 5degree C and 25degree C. Because the 
phosphate salt is freely soluble in water, the drug is in solution in these products. No 
visual changes or changes in odor were detected during the study. Stability-indicating 
HPLC analysis found little or no drug loss in any of the liquid products stored at either 
temperature after 60 days of storage. Study 3: Odusote and Nasipuri evaluated the 
stability of three syrup formulations (See Table 1 below) containing chloroquine 
phosphate 16 mg/mL prepared from bulk powder. The sucrose syrup formulation was 
prepared by adding the chloroquine phosphate powder and sodium benzoate to heated 
syrup and stirring until complete dissolution occurred. The flavor and color were then 
added. The other two formulations were prepared by dispersing the methylcellulose in 
some hot water followed by ice-cold water and subsequently keeping the mixture in a 
freezer. The other materials then were added and mixed well. After preparation, the 
syrups were packaged in amber bottles and stored at 5, 25, and 40degree C for 12 
weeks. Chloroquine content was assessed spectrophotometrically. No change in 
chloroquine concentration and no observable physical change were found in samples 
from any storage temperature during storage. If clear bottles were used instead of 
amber, exposure to light resulted in about 6% drug loss in eight weeks. If the syrup pH 
was adjusted from the original pH 4.5 to 4.9 down to pH 3.5 with citric acid (used to 
help mask the bitter taste), the chloroquine concentration remained constant over 12 
weeks at all temperatures. However, if 1% sodium carboxymethylcellulose was 
substituted as the viscosity agent, a white turbidity or precipitate appeared (depending 
on concentration) along with a sudden drop in viscosity, indicating an interaction with 
the chloroquine phosphate. Consequently, Odusote and Nasipuri recommended using 
only methylcellulose as the viscosity-imparting agent. Table 1. Chloroquine Phosphate 
Formulations Tested for Stability by Odusote and Nasipuri Formula 1: Chloroquine 
phosphate 1.6 g Sodium benzoate 0.2 g Essence of lemon grass 0.5 mL Yellow food 
color 0.2 mL Sucrose syrup 84% (w/v) qs 100mL Formula 2: Chloroquine phosphate 
1.6 g Sodium benzoate 0.2 g Saccharin sodium 0.05 g Essence of lemon grass 0.5 mL 
Yellow food color 0.2 mL Methylcellulose 1.12% solution qs 100 mL Formula 3: 
Chloroquine phosphate 1.6 g Sodium benzoate 0.2 g Talin 0.05 g Essence of lemon 
grass 0.5 mL Yellow food color 0.2 mL Methylcellulose 1.12% solution qs 100 mL 
Study 4: Mirochnick et al. attempted to determine the stability of a chloroquine 
phosphate suspension prepared from tablets. Although no loss of drug was found by 
HPLC analysis, substantial increases in drug concentration at various time points 
indicated a nonuniform dispersion of the drug might have existed. Study 5: Van Doorne 
et al. evaluated the suitability of several antimicrobial preservatives for use in 
chloroquine phosphate 16-mg/mL syrup containing sucrose 66%. Chloroform had been 
used previously, but it is carcinogenic, potentially toxic to liver and kidneys, and is 
volatile resulting in loss of protection over time. Benzalkonium chloride is unsuitable 
because of its taste and incompatibilities. The best result was obtained using sorbic 
acid 1.5 g/L along with citric acid 2 g/L to reduce the pH to 4. Methylparaben 1.8 g/L 
with propylparaben 0.2 g/L also was acceptable, although the latter system was not as 
effective against Aspergillus niger. Study 6: Chandibhamar et al. evaluated the stability 
of a taste-masked suspension of chloroquine. Chloroquine phosphate 1.7 g was 
dissolved in 40 mL of simple syrup containing glycerin 5% (v/v). Then 30 mL of hot 
syrup containing pamoate sodium 1.3 g and sodium bicarbonate 0.56 g was slowly 
mixed in at a rate of 5 mL per minute with constant stirring of 30 to 80 RPM. A 
precipitate of chloroquine pamoate was produced. The suspension was adjusted to pH 
6.0 and sodium benzoate 100 mg, amaranth, and raspberry flavor were added. The 
suspension was brought to 100 mL with additional syrup. The suspension exhibited a 
very slow rate of sedimentation. Spectroscopic analysis found the suspension remained 
stable over at least 42 days at 25 degree C with over 98% of the ion pair remaining and 
only 1.75% of free chloroquine present. Elevated temperature of 45 degree C resulted 
in an approximate doubling of the rate of free chloroquine formation. Bioavailability of 
this suspension was comparable with chloroquine phosphate liquid.
References
Allen LV Jr, Erickson MA. Stability of alprazolam, chloroquine phosphate, cisapride, 
enalapril maleate, and hydralazine hydrocloride in extemporaneously compounded oral 
liquids. Am J Health-Syst Pharm. 1998; 55:1915-20 
Chandibhammar V, Yadav MR, Murthy RSR. Studies on the development of taste-
masked suspension of chloroquine. Boll Chim Farm. 2004; 143:377-82 
Closson RG. Liquid dosage form of chloroquine. Drug Intell Clin Pharm. 1988; 22:347 
Mironchnick M, Barnett E, Clarke DF, et al. Stability of chloroquine in an 
extemporaneously prepared suspension stored at three temperatures. Pediatr Infect Dis 
J. 1994; 13:817-8 
Odusote MO, Nasipuri RN. Effect of pH and storage conditions on the stability of a 
novel chloroquine phosphate syrup formulation. Pharm Ind. 1988; 50:367-9 
Van Doorne H, Wieringa NF, Bosch EH, et al. The suitability of some preservatives in 
chloroquine phosphate syrup. Pharm Weekbl Sci Ed. 1988; 10:170-2 
5. Topical
Brouwers et al. developed a topical gel containing chloroquine phosphate for use as a 
microbicide against HIV-1 infection. The gel was prepared by adding a mixture of 
hydroxyethyl cellulose 1.6% wt/wt and glycerol 2.5% to a solution of methyl- and 
propylparabens 0.18% and 0.02%, respectively. When mixed, a clear and homogeneous 
gel formed. The pH of the gel was decreased by adding lactic acid 0.05% and adjusting 
to pH 4.5 by adding sodium hydroxide 1 M. Chloroquine phosphate powder was added 
to the gel in varying amounts of 0.3, 1.3, 3, 10, and 30 mg/g of gel and mixed 
thoroughly to assure complete dissolution and uniformity. Entrapped air was removed 
by using reduced pressure. The completed gels were packaged in capped syringes. The 
gels were clear and homogeneous with an osmolality of 300 mOsm/kg, a pH of 4.6, 
and a viscosity of 1.4 Pa s. Samples containing chloroquine phosphate 3 mg/g were 
stored at 40degree C and 75% relative humidity for three months. Little or no change 
in gel mass, pH, and osmolality occurred. Viscosity decreased by 14%, which is similar 
to changes observed in previously reported observations for hydroxyethyl cellulose 
gels. HPLC analysis found that little or no change in chloroquine concentrations 
occurred over the three-month test period.
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Adverse Reactions
• abdominal pain
• acute generalized exanthematous 
pustulosis (AGEP)
• agitation
• agranulocytosis
• alopecia
• anaphylactic shock
• anaphylactoid reactions
• angioedema
• anorexia
• anxiety
• aplastic anemia
• AV block
• blurred vision
• bundle-branch block
• cardiomyopathy
• confusion
• corneal deposits
• corneal opacification
• delirium
• depression
• diarrhea
• Drug Reaction with Eosinophilia and 
Systemic Symptoms (DRESS)
• dyskinesia
• elevated hepatic enzymes
• erythema multiforme
• exfoliative dermatitis
• hair discoloration
• hallucinations
• headache
• hearing loss
• hemolysis
• hemolytic anemia
• hepatitis
• hypoglycemia
• hyporeflexia
• hypotension
• insomnia
• macular degeneration
• myasthenia
• myopathy
• nausea
• neutropenia
• night blindness
• pancytopenia
• photosensitivity
• pruritus
• psoriasis
• psychosis
• QT prolongation
• retinopathy
• scotomata
• seizures
• skin discoloration
• Stevens-Johnson syndrome
• suicidal ideation
• thrombocytopenia
• tinnitus
• torsade de pointes
• torticollis
• toxic epidermal necrolysis
• urticaria
• ventricular fibrillation
• ventricular tachycardia
• visual impairment
• vomiting
• weakness
Irreversible maculopathy and macular degeneration have been reported with chloroquine or other 
4-aminoquinoline compounds during postmarketing use. Irreversible retinopathy with retinal 
pigment changes (bull's eye appearance) and visual field defects (paracentral scotomas) have been 
reported in patients receiving long-term or high-dose 4-aminoquinoline therapy. Visual 
impairment (i.e., blurred vision and difficulty in focusing or accommodation), nyctalopia (night 
blindness), scotomatous vision with field defects of paracentral, pericentral ring types, and 
typically temporal scotomata (e.g., difficulty in reading with words tending to disappear, seeing 
half an object, misty vision, and fog before the eyes), and reversible corneal opacification (corneal 
deposits) have been reported. For patients with significant risk factors, monitoring should include 
annual examinations which include best corrected distance visual acuity (BCVA), automated 
threshold visual field (VF), and spectral domain optical coherence tomography (SD-OCT). For 
individuals without significant risk factors, annual exams can usually be deferred until 5 years of 
treatment. Discontinue chloroquine if ocular toxicity is suspected, and monitor the patient closely 
as retinal changes and visual disturbances may progress after cessation of therapy.[29758]
Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative 
dermatitis, pleomorphic skin eruptions, skin and mucosal pigmentary changes (skin discoloration), 
lichen planus-like eruptions, pruritus, drug reaction with eosinophilia and systemic symptoms 
(DRESS), photosensitivity, hair loss (alopecia), bleaching of hair pigment (hair discoloration), 
urticaria, anaphylactoid reactions or anaphylactic shock, and angioedema have been reported 
during postmarketing use of chloroquine or other 4-aminoquinoline compounds. An acute attack 
of psoriasis can be precipitated by chloroquine in predisposed patients.[29758]
Chloroquine has been associated with acute generalized exanthematous pustulosis (AGEP). The 
non-follicular, pustular, erythematous rash starts suddenly and is associated with fever above 38 
degrees C. Drugs are the main cause of AGEP. A period of 2 to 3 weeks after an inciting drug 
exposure appears necessary for a first episode of AGEP. Unintentional reexposure may cause a 
second episode within 2 days.[27736]
Hematological adverse reactions have been reported during postmarketing use of chloroquine or 
other 4-aminoquinoline compounds and include reversible agranulocytosis, aplastic anemia, 
pancytopenia, neutropenia, and thrombocytopenia. Chloroquine may cause hemolysis and 
hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD 
deficiency).[29758]
During postmarketing use, chloroquine and/or other 4-aminoquinoline compounds have been 
associated with sensorimotor disorders as well as skeletal muscle myopathy or neuromyopathy 
leading to progressive weakness (myasthenia) and atrophy of proximal muscle groups, depressed 
tendon reflexes (hyporeflexia), and abnormal nerve conduction. Periodically test knee and ankle 
reflexes to detect any evidence of muscular weakness. Discontinue chloroquine if weakness 
develops.[29758]
Nerve type deafness, tinnitus, and reduced hearing (hearing loss) in patients with preexisting 
auditory damage have been reported during postmarketing use of chloroquine or other 4-
aminoquinoline compounds. Discontinue chloroquine with any hearing defects, and monitor the 
patient closely.[29758]
Cardiovascular adverse reactions associated with chloroquine or other 4-aminoquinoline 
compounds during postmarketing include cardiomyopathy (which may result in cardiac failure 
and in some cases fatal outcome), electrocardiogram (ECG) changes (particularly, inversion or 
flattening of the T-wave with widening of the QRS complex), and hypotension. Cardiac 
arrhythmias, conduction disorders such as bundle-branch block and AV block, QT prolongation, 
torsade de pointes (TdP), ventricular arrhythmias (e.g., ventricular tachycardia, ventricular 
fibrillation) have been reported, including fatal cases. The risk is greater with higher doses, 
although cases have been reported with therapeutic doses. Chronic toxicity should be considered 
when conduction disorders, such as bundle-branch block or AV block, are diagnosed. Additionally, 
cases of cardiomyopathy resulting in cardiac failure with some cases of fatal outcome have been 
reported with chloroquine. Prompt discontinuation of chloroquine may prevent life-threatening 
complications if cardiotoxicity is suspected.[28225] [28229] [28230] [28231] [29758]
Adverse gastrointestinal effects noted with chloroquine or other 4-aminoquinoline compounds 
during postmarketing include hepatitis, elevated hepatic enzymes, nausea, vomiting, abdominal 
pain/cramps, diarrhea, and anorexia.[29758] Gastric effects can be minimized by taking 
chloroquine with food.[61673]
Nervous system adverse reactions associated with chloroquine or other 4-aminoquinoline 
compounds during postmarketing include headache (usually mild and transient), seizures, 
polyneuropathy, acute extrapyramidal symptoms (e.g., dystonia, dyskinesia, tongue protrusion, 
torticollis), and neuropsychiatric changes including psychosis, delirium, anxiety, agitation, 
insomnia, hallucinations, confusion, personality changes, depression, and suicidal 
ideation/behavior. Extrapyramidal symptoms usually resolve after treatment discontinuation 
and/or symptomatic treatment.[29758]
Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that 
could be life threatening in patients treated with or without antidiabetic medications. Monitor 
blood glucose and adjust treatment as necessary in patients presenting with clinical symptoms of 
hypoglycemia during chloroquine treatment.[29758]
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Contraindications/Precautions
Absolute contraindications are italicized.
• chloroquine hypersensitivity
• ocular disease
• accidental exposure 
• alcoholism 
• antimicrobial resistance 
• apheresis 
• Asian patients 
• AV block 
• bradycardia 
• breast-feeding 
• cardiomyopathy 
• celiac disease 
• children 
• diabetes mellitus 
• Fabry disease 
• females 
• fever 
• G6PD deficiency 
• geriatric 
• hearing impairment 
• heart failure 
• hepatic disease 
• human immunodeficiency virus (HIV) 
infection 
• hydroxychloroquine hypersensitivity 
• hyperparathyroidism 
• hypocalcemia 
• hypoglycemia 
• hypokalemia 
• hypomagnesemia 
• hypothermia 
• hypothyroidism 
• infants 
• infertility 
• long QT syndrome 
• myocardial infarction 
• neonates 
• neurological disease 
• pheochromocytoma 
• porphyria 
• pregnancy 
• psoriasis 
• QT prolongation 
• renal failure 
• renal impairment 
• rheumatoid arthritis 
• seizure disorder 
• seizures 
• sickle cell disease 
• sleep deprivation 
• stroke 
• systemic lupus erythematosus (SLE) 
Chloroquine is reported in the literature to be a weak genotoxic agent that may elicit both gene 
mutations and chromosomal/DNA breaks. Mechanisms may involve DNA intercalation or 
induction of oxidative stress. Both positive and negative results have been reported with in vitro 
reverse gene mutation assays and with in vivo animal studies. The chromosomal effects were not 
observed when chloroquine was administered to animals orally.[29758]
Antimicrobial resistance to chloroquine therapy is widespread in P. falciparum and is reported in 
P. vivax. Prior to chloroquine use, it should be ascertained whether chloroquine is appropriate for 
use based on resistance patterns. Information regarding the geographic areas where resistance to 
chloroquine occurs is available from the Centers for Disease Control and Prevention.[29758]
Use of chloroquine for indications other than acute malaria is contraindicated in patients with 
ocular disease, specifically those who have retinal or visual field changes of any etiology. 
Irreversible retinal damage has been observed in some patients who received chloroquine. 
Significant risk factors for retinal damage include daily doses of chloroquine phosphate more than 
2.3 mg/kg of actual body weight, duration of use more than 5 years, subnormal glomerular 
filtration (renal impairment or renal failure), use of some concomitant drug products such as 
tamoxifen, and concurrent macular disease. Baseline ophthalmological examination should be 
performed within the first year of starting chloroquine and should include best corrected distance 
visual acuity (BCVA), automated threshold visual field (VF) of the central 10 degrees (with 
retesting if an abnormality is noted), and spectral domain optical coherence tomography (SD-
OCT). In Asian patients, retinal toxicity may first be noticed outside the macula, and VF testing 
should be performed in the central 24 degrees instead of the central 10 degrees. For patients with 
significant risk factors, monitoring should include annual examinations which include BCVA, VF, 
and SD-OCT. For individuals without significant risk factors, annual exams can usually be 
deferred until 5 years of treatment. Discontinue chloroquine if ocular toxicity is suspected, and 
monitor the patient closely as retinal changes and visual disturbances may progress after cessation 
of therapy.[29758] The use of chloroquine should be approached with caution in patients with 
Fabry disease, particularly those with ocular symptoms. The drug can cause a keratopathy that is 
clinically and ultrastructurally indistinguishable from keratopathy caused by Fabry disease; this 
drug-induced keratopathy is reversible with drug cessation. In addition, chloroquine poses a 
theoretical risk of decreased intracellular alpha-galactosidase A activity in Fabry disease patients. 
Chloroquine has been reported to induce clinical symptoms that mimic those of Fabry disease, 
including formation of inclusion bodies that are biochemically and ultrastructurally similar in most 
of the cells affected by Fabry disease (e.g., striated muscle, smooth muscle, etc.). The 
distinguishing factor is that the ultrastructural features of chloroquine toxicity in striated muscle, 
curvilinear bodies, are not present in renal cells.[30609]
Chloroquine is contraindicated in patients with known chloroquine hypersensitivity, or with a 
known allergy to 4-aminoquinolines. Patients with hydroxychloroquine hypersensitivity may have 
cross sensitivity to chloroquine.[29758]
QT prolongation, torsade de pointes (TdP), and ventricular arrhythmias have been reported with 
chloroquine use. The risk is greater with higher doses, although cases have been reported with 
therapeutic doses.[28225] [28229] [28230] [28231] [29758] Use chloroquine with caution in patients 
with conditions that may increase the risk of QT prolongation including congenital long QT 
syndrome, bradycardia, AV block, heart failure, stress-related cardiomyopathy, myocardial 
infarction, stroke, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving 
medications known to prolong the QT interval or cause electrolyte imbalances. Females, geriatric
patients, patients with sleep deprivation, pheochromocytoma, sickle cell disease, hypothyroidism, 
hyperparathyroidism, hypothermia, systemic inflammation (e.g., human immunodeficiency virus 
(HIV) infection, fever, and some autoimmune diseases including rheumatoid arthritis, systemic 
lupus erythematosus (SLE), and celiac disease) and patients undergoing apheresis procedures 
(e.g., plasmapheresis [plasma exchange], cytapheresis) may also be at increased risk for QT 
prolongation.[28432] [28457] [29758] [56592] [65180] In patients taking chloroquine with another 
drug that also prolongs the QT interval (see Therapeutic Drug Monitoring for recommendations 
specific to azithromycin with chloroquine used together for COVID-19), obtain a pre-treatment 
QTc using a standard 12-lead ECG, telemetry, or mobile ECG device. Obtain baseline electrolytes, 
including calcium, magnesium, and potassium. Determine if the patient is currently on any QT-
prolonging medications that can be discontinued. Document high-risk cardiovascular and 
comorbid conditions. If the baseline QTc is 500 msec or more and/or the patient has an inherent 
tendency to develop an exaggerated QTc response (i.e., change of 60 msec or more), correct 
contributing electrolyte abnormalities, review and discontinue other unnecessary QTc prolonging 
medications, and proceed with close QTc surveillance. Obtain an initial on-therapy QTc 
approximately 2 to 4 hours after the first dose and then again at 48 and 96 hours after treatment 
initiation. If the baseline QTc is 460 to 499 msec (prepubertal), 470 to 499 msec (postpubertal 
males), or 480 to 499 msec (postpubertal females), correct contributing electrolyte abnormalities, 
review and discontinue other unnecessary QTc prolonging medications, and obtain an initial on-
therapy QTc 48 and 96 hours after treatment initiation. If the baseline QTc is less than 460 msec 
(prepubertal), less than 470 msec (postpubertal males), or less than 480 msec (postpuberal 
females), correct electrolyte abnormalities and obtain an initial on-therapy QTc 48 and 96 hours 
after treatment initiation.[65170] Consider chronic chloroquine toxicity when conduction disorders, 
such as bundle-branch block or AV block, are diagnosed. Cases of cardiomyopathy resulting in 
cardiac failure, sometimes fatal, have been reported with chloroquine. Prompt discontinuation of 
chloroquine may prevent life-threatening complications if cardiotoxicity is suspected.[29758]
Chloroquine should not be used in patients with psoriasis unless the benefit to the patient 
outweighs the potential risks because it may precipitate a severe attack of psoriasis.[29758]
Chloroquine should be used with caution in patients with hepatic disease or alcoholism because 
the drug is metabolized in the liver and accumulation can occur producing toxic effects. Patients 
receiving other hepatotoxic drugs also should be treated with caution.[29758]
Chloroquine should be used with caution in patients with neurological disease including 
preexisting hearing impairment or seizure disorder. Polyneuritis, ototoxicity, seizures, 
neuromyopathy, and acute extrapyramidal symptoms (dystonia, dyskinesia, tongue protrusion, 
torticollis) have occurred with chloroquine therapy. Symptoms of muscle weakness and response 
of knee and ankle reflexes should be investigated regularly. If muscle weakness, extrapyramidal 
symptoms, or any defects in hearing occur during chloroquine therapy, the drug should be 
discontinued immediately and the patient observed closely.[29758]
Chloroquine can exacerbate porphyria or may cause hemolysis in patients with glucose-6-
phosphate dehydrogenase deficiency (G6PD deficiency). Use chloroquine with caution in patients 
with these conditions. Blood monitoring for hemolytic anemia in G6PD deficiency patients may 
be necessary, particularly with concomitant use of other medications associated with hemolysis.
[29758]
Use chloroquine with caution in patients with hypoglycemia or diabetes mellitus. Chloroquine can 
cause severe, life-threatening hypoglycemia in patients with or without antidiabetic medications. 
Warn patients about the risk of hypoglycemia and the associated clinical signs and symptoms. 
Monitor blood glucose and adjust treatment as necessary in patients presenting with clinical 
symptoms of hypoglycemia during chloroquine treatment.[29758]
Children are especially sensitive to the 4-aminoquinoline compounds. Fatalities have been 
reported after accidental exposure of chloroquine; some cases involved relatively small doses 
(e.g., 0.75 g or 1 g in a 3-year-old child). Strongly warn patients to keep chloroquine out of the 
reach of pediatric patients, including neonates, infants, children, and adolescents.[29758]
Weigh the benefit of chloroquine prophylaxis or treatment of malaria against the potential risk to 
the fetus, and consider the drug's potential to remain in the body for several months after 
discontinuation of therapy.[29758] [63990] [64059] In humans at recommended doses for 
prophylaxis and treatment of malaria, observational studies as well as a meta-analysis, including a 
small number of prospective studies with chloroquine during pregnancy, have shown no increase 
in the rate of birth defects or spontaneous abortions.[29758] Guidelines recommend chloroquine as 
a treatment option for acute malaria and for prophylaxis in pregnant women during all trimesters. 
Chloroquine crosses the placenta, but the potential damage to the mother from malaria is greater 
than the drug's risk to the fetus. Weekly prophylactic doses appear to have minimal adverse effects 
when administered during pregnancy.[63990] [64059] Animal studies showed embryo-fetal 
developmental toxicity at doses 3 to 16 times the maximum recommended therapeutic dose and 
the potential of genotoxicity in some test systems. Autoradiographic studies have shown 
accumulation in the eyes and ears when chloroquine is administered at the start or end of gestation 
in animal studies.[29758]
Use caution when administering chloroquine to breast-feeding women. Chloroquine is excreted 
into breast milk. The excretion of chloroquine and the major metabolite, desethylchloroquine, in 
breast milk was investigated in 11 lactating mothers following a single oral dose of chloroquine 
(600 mg base).The maximum daily dose of the drug that the infant received from breast-feeding 
was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. Separate 
chemoprophylaxis for an infant is required.[29758] However, previous American Academy of 
Pediatrics (AAP) recommendations consider chloroquine usually compatible with breast-feeding, 
and chloroquine has an established dosage in infants.[27500]
Chloroquine should be used with caution in males because animal studies suggest that infertility is 
possible; after 30 days of oral treatment, testosterone levels and weight of testes, epididymis, 
seminal vesicles, and prostate decreased.[29758]
Revision Date: 04/10/2020 04:22:06 PM 
References
27500 – American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and 
other chemicals into human milk. Pediatrics 2001;108(3):776-789.
28225 – CredibleMeds. Drugs to avoid in congenital long QT. Available on the World Wide Web 
at http://www.crediblemeds.org.
28229 – Demaziere J, Fourcade JM, Busseuil CT, et al. The hazards of chloroquine self 
prescription in west Africa. J Toxicol Clin Toxicol 1995;33:369-70.
28230 – Mansfield RJ, Thomas RD. Recurrent syncope. Drug induced long QT syndrome. 
Postgrad Med J 2001;77:344, 352-3.
28231 – Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents 
torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin 
Electrophysiol 2002;25:1612-5.
28432 – Roden, DM. Drug-induced prolongation of the QT interval. New Engl J Med 
2004;350:1013-22.
28457 – Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related 
QT interval prolongation. Pharmacotherapy 2003;23:881-908.
29758 – Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 
Oct.
30609 – Albay D, Adler SG, Philipose J, et al. Chloroquine-induced lipidosis mimicking Fabry 
disease. Mod Pathol 2005;18:733-8.
56592 – van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval 
prolongation. Br J Clin Pharmacol 2010;70(1):16-23.
63990 – Arguin PM, Tan KR. Chapter 3. Infectious diseases related to travel. Malaria. In. Centers 
for Disease Control and Prevention. 2018 Yellow Book - Traveler's Health. Atlanta: U.S. 
Department of Health and Human Services, Public Health Service. 
https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/malaria
64059 – Centers for Disease Control and Prevention. Treatment of malaria (guidelines for 
clinicians). Atlanta, GA: US Department of Health and Human Services; 2019. 
https://www.cdc.gov/malaria/diagnosis_treatment/treatment.html.
65170 – Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for 
navigating and circumventing the QTc prolonging and torsadogenic potential of possible 
pharmacotherapies for COVID-19 [published online ahead of print, March 25, 2020]. Mayo Clin 
Proc 2020;95.
65180 – Woosley RL, Heise CW, Gallo T, et al. QTFactors List. Oro Valley, AZ: AZCERT, Inc.; 
Accessed March 31, 2020. Available on the World Wide Web at: https://crediblemeds.org/ndfa-list/
Mechanism of Action
Chloroquine, a 4-aminoquinoline, is an anti-protozoal agent. The precise mechanism is unknown. 
Chloroquine may exert its effect against Plasmodium species by concentrating in the acid vesicles 
of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its 
interaction with DNA. Chloroquine is not active against gametocytes and the exoerythrocytic 
forms, including the hypnozoite stage (P. vivax and P. ovale) of the Plasmodium parasites. 
Organisms with reduced susceptibilities to hydroxychloroquine also show reduced susceptibilities 
to chloroquine.[29758]
Although the mechanisms underlying the antiinflammatory and immunomodulatory effects of 
chloroquine are unknown, several possible mechanisms of action have been proposed. It is unclear 
if these mechanisms work similarly for rheumatic and autoimmune diseases. Potential 
mechanisms include reduced cytokine production, inhibition of immune effector cells, inhibition 
of platelet function, protection of the cell surface from external disturbances, competitive binding 
to nucleic acid ligands or toll-like receptors (TLRs), interference with lysosomal function, 
reduction of leakage of lysosomal enzymes, and interference with endosomal NADPH oxidase 
(NOX).[61727] [61728] [61729]
There are several potential mechanisms by which chloroquine may be active against severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). These include inhibition of viral enzymes or 
processes such as viral DNA and RNA polymerase, viral protein glycosylation, virus assembly, 
new virus particle transport, and virus release. Other mechanisms may also involve ACE2 cellular 
receptor inhibition, acidification at the surface of the cell membrane inhibiting fusion of the virus, 
and immunomodulation of cytokine release.[61729] [61732] [65120] [65121] [65139] [65140] [65141]
[65142] [65143]
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Pharmacokinetics
Chloroquine is administered orally. It is widely distributed into body tissues, with higher 
concentrations in the liver, kidneys, spleen, and lungs. Leukocytes also concentrate the drug. 
Smaller amounts of the drug are found in the brain and spinal cord. Cells containing melanin in 
the eyes and skin bind strongly to chloroquine. The drug also concentrates in erythrocytes and is 
bound to platelets and granulocytes. It is about 55% bound to plasma protein.[29758] [61731]
[62151]
Excretion of chloroquine is largely through urine, but this is a slow process and may be increased 
by acidification of the urine. Chloroquine undergoes appreciable degradation in the body, and the 
major metabolite is desethylchloroquine. Slightly more than half of a dose is excreted in urine as 
unchanged drug and about 25% as the major metabolite; bisdesethylchloroquine and other 
metabolic products are found in small amounts. A small portion of the unabsorbed drug is excreted 
in the feces. Elimination appears to take place in a biphasic manner. The elimination half-life is 
108 to 291 hours.[29758] [61731] [62151]
Affected cytochrome P450 isoenzymes and drug transporters: CYP2C8, CYP2D6, CYP3A4, P-gp
In vitro data suggest that chloroquine is metabolized primarily by CYP2C8 and CYP3A4, and to a 
much lesser extent, by CYP2D6.[65236] [65239] It has also been shown to be an inhibitor of the 
drug transporter P-glycoprotein (P-gp).[65237]
Route-Specific Pharmacokinetics
• Oral Route
After oral administration, chloroquine is rapidly and almost completely absorbed from 
the gastrointestinal tract.[29758][62151] The Tmax is 2.7 to 6.9 hours with a Cmax of 
283 to 1,430 ng/mL and an AUC of 8.2 to 140 mcg x hour/mL.[62151] A single study 
showed that the AUC in patients with malaria was higher than in normal volunteers 
(281 vs. 122 mcg x mL/L x hour).[61760]
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Pregnancy/Breast-feeding
Pregnancy
Weigh the benefit of chloroquine prophylaxis or treatment of malaria against the potential risk to 
the fetus, and consider the drug's potential to remain in the body for several months after 
discontinuation of therapy.[29758] [63990] [64059] In humans at recommended doses for 
prophylaxis and treatment of malaria, observational studies as well as a meta-analysis, including a 
small number of prospective studies with chloroquine during pregnancy, have shown no increase 
in the rate of birth defects or spontaneous abortions.[29758] Guidelines recommend chloroquine as 
a treatment option for acute malaria and for prophylaxis in pregnant women during all trimesters. 
Chloroquine crosses the placenta, but the potential damage to the mother from malaria is greater 
than the drug's risk to the fetus. Weekly prophylactic doses appear to have minimal adverse effects 
when administered during pregnancy.[63990] [64059] Animal studies showed embryo-fetal 
developmental toxicity at doses 3 to 16 times the maximum recommended therapeutic dose and 
the potential of genotoxicity in some test systems. Autoradiographic studies have shown 
accumulation in the eyes and ears when chloroquine is administered at the start or end of gestation 
in animal studies.[29758]
Breast-Feeding
Use caution when administering chloroquine to breast-feeding women. Chloroquine is excreted 
into breast milk. The excretion of chloroquine and the major metabolite, desethylchloroquine, in 
breast milk was investigated in 11 lactating mothers following a single oral dose of chloroquine 
(600 mg base).The maximum daily dose of the drug that the infant received from breast-feeding 
was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. Separate 
chemoprophylaxis for an infant is required.[29758] However, previous American Academy of 
Pediatrics (AAP) recommendations consider chloroquine usually compatible with breast-feeding, 
and chloroquine has an established dosage in infants.[27500]
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Interactions
Level 1 (Severe)
• Cisapride
• Dronedarone
• Pimozide
• Thioridazine
Level 2 (Major)
• Acarbose
• Acetohexamide
• Aclidinium; Formoterol
• Albiglutide
• Albuterol
• Albuterol; Ipratropium
• Alfuzosin
• Alogliptin
• Alogliptin; Metformin
• Alogliptin; Pioglitazone
• Alpha-glucosidase Inhibitors
• Aluminum Hydroxide
• Aluminum Hydroxide; Magnesium 
Carbonate
• Aluminum Hydroxide; Magnesium 
Hydroxide
• Aluminum Hydroxide; Magnesium 
Hydroxide; Simethicone
• Aluminum Hydroxide; Magnesium 
Trisilicate
• Amiodarone
• Amitriptyline
• Amitriptyline; Chlordiazepoxide
• Amoxicillin; Clarithromycin; 
Lansoprazole
• Amoxicillin; Clarithromycin; 
Omeprazole
• Anagrelide
• Antacids
• Apomorphine
• Arformoterol
• Aripiprazole
• Arsenic Trioxide
• Artemether; Lumefantrine
• Asenapine
• Aspirin, ASA; Citric Acid; Sodium 
Bicarbonate
• Atomoxetine
• Azithromycin
• Bedaquiline
• Bismuth Subcitrate Potassium; 
Metronidazole; Tetracycline
• Bismuth Subsalicylate; Metronidazole; 
Tetracycline
• Budesonide; Formoterol
• Buprenorphine
• Buprenorphine; Naloxone
• Calcium Carbonate
• Calcium Carbonate; Magnesium 
Hydroxide
• Calcium Carbonate; Risedronate
• Calcium Carbonate; Simethicone
• Canagliflozin
• Canagliflozin; Metformin
• Ceritinib
• Chlorpromazine
• Chlorpropamide
• Cimetidine
• Ciprofloxacin
• Citalopram
• Clarithromycin
• Clofazimine
• Clomipramine
• Clozapine
• Codeine; Phenylephrine; Promethazine
• Codeine; Promethazine
• Crizotinib
• Cyclosporine
• Dapagliflozin
• Dapagliflozin; Metformin
• Dapagliflozin; Saxagliptin
• Dasatinib
• Degarelix
• Desflurane
• Desipramine
• Deutetrabenazine
• Dextromethorphan; Promethazine
• Dextromethorphan; Quinidine
• Dipeptidyl Peptidase-4 Inhibitors
• Disopyramide
• Dofetilide
• Dolasetron
• Dolutegravir; Rilpivirine
• Donepezil
• Donepezil; Memantine
• Doxepin
• Droperidol
• Dulaglutide
• Efavirenz
• Efavirenz; Emtricitabine; Tenofovir
• Efavirenz; Lamivudine; Tenofovir 
Disoproxil Fumarate
• Eliglustat
• Empagliflozin
• Empagliflozin; Linagliptin
• Empagliflozin; Linagliptin; Metformin
• Empagliflozin; Metformin
• Emtricitabine; Rilpivirine; Tenofovir 
alafenamide
• Emtricitabine; Rilpivirine; Tenofovir 
disoproxil fumarate
• Encorafenib
• Enflurane
• Entrectinib
• Eribulin
• Ertugliflozin
• Ertugliflozin; Metformin
• Ertugliflozin; Sitagliptin
• Erythromycin
• Erythromycin; Sulfisoxazole
• Escitalopram
• Exenatide
• Ezogabine
• Fingolimod
• Flecainide
• Fluconazole
• Fluoxetine
• Fluoxetine; Olanzapine
• Fluphenazine
• Fluticasone; Salmeterol
• Fluticasone; Umeclidinium; Vilanterol
• Fluticasone; Vilanterol
• Fluvoxamine
• Formoterol
• Formoterol; Mometasone
• Foscarnet
• Gemifloxacin
• Gemtuzumab Ozogamicin
• Gilteritinib
• Glasdegib
• Glimepiride
• Glimepiride; Pioglitazone
• Glimepiride; Rosiglitazone
• Glipizide
• Glipizide; Metformin
• Glyburide
• Glyburide; Metformin
• Glycopyrrolate; Formoterol
• Goserelin
• Granisetron
• Halogenated Anesthetics
• Haloperidol
• Halothane
• Histrelin
• Hydroxyzine
• Ibutilide
• Iloperidone
• Imipramine
• Incretin Mimetics
• Indacaterol
• Indacaterol; Glycopyrrolate
• Inotuzumab Ozogamicin
• Insulin Aspart
• Insulin Aspart; Insulin Aspart Protamine
• Insulin Degludec
• Insulin Degludec; Liraglutide
• Insulin Detemir
• Insulin Glargine
• Insulin Glargine; Lixisenatide
• Insulin Glulisine
• Insulin Lispro
• Insulin Lispro; Insulin Lispro Protamine
• Insulin, Inhaled
• Insulins
• Isoflurane
• Isophane Insulin (NPH)
• Itraconazole
• Ivosidenib
• Ketoconazole
• Lanthanum Carbonate
• Lapatinib
• Lefamulin
• Lente Insulin
• Lenvatinib
• Leuprolide
• Leuprolide; Norethindrone
• Levalbuterol
• Levofloxacin
• Linagliptin
• Linagliptin; Metformin
• Liraglutide
• Lithium
• Lixisenatide
• Lofexidine
• Lomefloxacin
• Long-acting beta-agonists
• Loperamide
• Loperamide; Simethicone
• Lopinavir; Ritonavir
• Macimorelin
• Magnesium Hydroxide
• Maprotiline
• Mefloquine
• Meglitinides
• Meperidine; Promethazine
• Metaproterenol
• Metformin
• Metformin; Pioglitazone
• Metformin; Repaglinide
• Metformin; Rosiglitazone
• Metformin; Saxagliptin
• Metformin; Sitagliptin
• Methadone
• Metronidazole
• Midostaurin
• Mifepristone
• Miglitol
• Mirtazapine
• Moxifloxacin
• Nateglinide
• Nilotinib
• Norfloxacin
• Nortriptyline
• Octreotide
• Ofloxacin
• Olanzapine
• Olodaterol
• Omeprazole; Sodium Bicarbonate
• Ondansetron
• Osilodrostat
• Osimertinib
• Oxaliplatin
• Paliperidone
• Panobinostat
• Pasireotide
• Pazopanib
• Penicillamine
• Pentamidine
• Perphenazine
• Perphenazine; Amitriptyline
• Phenylephrine; Promethazine
• Pimavanserin
• Pioglitazone
• Pirbuterol
• Pitolisant
• Posaconazole
• Pramlintide
• Primaquine
• Procainamide
• Prochlorperazine
• Promethazine
• Propafenone
• Protriptyline
• Quetiapine
• Quinidine
• Quinine
• Rabies Vaccine
• Ranolazine
• Regular Insulin
• Regular Insulin; Isophane Insulin (NPH)
• Repaglinide
• Ribociclib
• Ribociclib; Letrozole
• Rilpivirine
• Risperidone
• Romidepsin
• Rosiglitazone
• Salmeterol
• Saquinavir
• Saxagliptin
• Semaglutide
• Sertraline
• Sevoflurane
• SGLT2 Inhibitors
• Short-acting beta-agonists
• Simvastatin; Sitagliptin
• Siponimod
• Sitagliptin
• Sodium Bicarbonate
• Solifenacin
• Sorafenib
• Sotalol
• Sulfonylureas
• Sunitinib
• Tacrolimus
• Tamoxifen
• Telavancin
• Telithromycin
• Terbutaline
• Tetrabenazine
• Thiazolidinediones
• Tiotropium; Olodaterol
• Tolazamide
• Tolbutamide
• Tolterodine
• Toremifene
• Trazodone
• Tricyclic antidepressants
• Trifluoperazine
• Trimipramine
• Triptorelin
• Ultralente Insulin
• Umeclidinium; Vilanterol
• Vandetanib
• Vardenafil
• Vemurafenib
• Venlafaxine
• Vigabatrin
• Voriconazole
• Vorinostat
• Ziprasidone
Level 3 (Moderate)
• Ampicillin
• Articaine; Epinephrine
• Atropine; Hyoscyamine; Phenobarbital; 
Scopolamine
• Belladonna Alkaloids; Ergotamine; 
Phenobarbital
• Betrixaban
• Bupivacaine
• Bupivacaine Liposomal
• Bupivacaine; Lidocaine
• Carbamazepine
• Chloroprocaine
• Cobimetinib
• Dabigatran
• Dapsone
• Digoxin
• Edoxaban
• Interferon Alfa-2a
• Interferon Alfa-2b
• Interferon Alfa-2b; Ribavirin
• Interferon Alfa-n3
• Interferon Alfacon-1
• Interferon Beta-1a
• Interferon Beta-1b
• Interferon Gamma-1b
• Interferons
• Lidocaine
• Mepivacaine
• Mepivacaine; Levonordefrin
• Peginterferon Alfa-2a
• Peginterferon Alfa-2b
• Peginterferon beta-1a
• Penicillin G Benzathine; Penicillin G 
Procaine
• Penicillin G Procaine
• Phenobarbital
• Phenytoin
• Ponatinib
• Prilocaine
• Prilocaine; Epinephrine
• Ropivacaine
• Succinylcholine
• Tetracaine
• Trametinib
Level 4 (Minor)
• Praziquantel • Telbivudine
Acarbose: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the alpha-glucosidase inhibitors, are coadministered. A decreased 
dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in 
patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Acetohexamide: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Aclidinium; Formoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Albiglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Albuterol: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Beta-agonists may be associated with adverse 
cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists as compared to short-
acting beta-agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Albuterol; Ipratropium: (Major) Avoid coadministration of chloroquine with short-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists as compared to short-
acting beta-agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Alfuzosin: (Major) Avoid coadministration of chloroquine with alfuzosin due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Alfuzosin may prolong the QT interval in a dose-dependent 
manner. [28229] [28230] [28231] [28261] [65157] [65170]
Alogliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Alogliptin; Metformin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Alogliptin; Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are 
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe 
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an 
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Alpha-glucosidase Inhibitors: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the alpha-glucosidase inhibitors, are 
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe 
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an 
antidiabetic agent. [29758]
Aluminum Hydroxide: (Major) Chloroquine absorption may be reduced by antacids. Administer 
chloroquine and antacids at least 4 hours apart. [29758] [30285]
Aluminum Hydroxide; Magnesium Carbonate: (Major) Chloroquine absorption may be reduced 
by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285]
Aluminum Hydroxide; Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced 
by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285]
Aluminum Hydroxide; Magnesium Hydroxide; Simethicone: (Major) Chloroquine absorption may 
be reduced by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285]
Aluminum Hydroxide; Magnesium Trisilicate: (Major) Chloroquine absorption may be reduced by 
antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30285]
Amiodarone: (Major) Avoid coadministration of chloroquine with amiodarone due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Amiodarone, a Class III antiarrhythmic agent, is associated with a 
well-established risk of QT prolongation and torsade de pointes (TdP). Although the frequency of 
TdP is less with amiodarone than with other Class III agents, amiodarone is still associated with a 
risk of TdP. Due to the extremely long half-life of amiodarone, a drug interaction is possible for 
days to weeks after discontinuation of amiodarone. [28224] [28229] [28230] [28231] [28432] [28457]
[65157] [65170]
Amitriptyline: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants 
(TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. TCAs share pharmacologic properties 
similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in 
overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Amitriptyline; Chlordiazepoxide: (Major) Avoid coadministration of chloroquine with tricyclic 
antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, 
obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent 
ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share 
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT 
interval, particularly in overdose or with higher-dose prescription therapy (elevated serum 
concentrations). [28225] [28229] [28230] [28231] [28415] [28416] [29758] [65157] [65170]
Amoxicillin; Clarithromycin; Lansoprazole: (Major) Avoid coadministration of chloroquine with 
clarithromycin due to the increased risk of QT prolongation. If use together is necessary, obtain an 
ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG 
monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. Clarithromycin is 
associated with an established risk for QT prolongation and TdP. [28229] [28230] [28231] [28238]
[29758] [59321] [65157] [65170]
Amoxicillin; Clarithromycin; Omeprazole: (Major) Avoid coadministration of chloroquine with 
clarithromycin due to the increased risk of QT prolongation. If use together is necessary, obtain an 
ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG 
monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. Clarithromycin is 
associated with an established risk for QT prolongation and TdP. [28229] [28230] [28231] [28238]
[29758] [59321] [65157] [65170]
Ampicillin: (Moderate) Administer oral ampicillin 2 hours before or 2 hours after chloroquine. In 
a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. 
The reduction of ampicillin bioavailability could be attributed to slower gastric emptying and 
enhancement of gut motility produced by chloroquine. [29758] [61761]
Anagrelide: (Major) Avoid coadministration of chloroquine with anagrelide due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. TdP and ventricular tachycardia have been reported with 
anagrelide. In addition, dose-related increases in mean QTc and heart rate were observed in 
healthy subjects. [28229] [28230] [28231] [29758] [30163] [65157] [65170]
Antacids: (Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine 
and antacids at least 4 hours apart. [29758] [30285]
Apomorphine: (Major) Avoid coadministration of chloroquine with apomorphine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Limited data indicate that QT prolongation is possible 
with apomorphine administration; the change in QTc interval is not significant in most patients 
receiving dosages within the manufacturer's guidelines. [28229] [28230] [28231] [28661] [29758]
[65157] [65170]
Arformoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due 
to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Beta-agonists may be associated with adverse 
cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Aripiprazole: (Major) Avoid coadministration of chloroquine with aripiprazole due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. QT prolongation has occurred during therapeutic use of 
aripiprazole and following overdose. [28229] [28230] [28231] [29758] [42845] [53394] [60196] [65157]
[65170]
Arsenic Trioxide: (Major) Avoid coadministration of chloroquine with arsenic trioxide due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. TdP, QT interval prolongation, and complete 
atrioventricular block have been reported with arsenic trioxide use. [28226] [28229] [28230] [28231]
[65157] [65170]
Artemether; Lumefantrine: (Major) Avoid coadministration of chloroquine with artemether; 
lumefantrine due to the increased risk of QT prolongation. If use together is necessary, obtain an 
ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG 
monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. Artemether; lumefantrine 
is associated with prolongation of the QT interval. [28229] [28230] [28231] [29758] [35401] [65157]
[65170]
Articaine; Epinephrine: (Moderate) Coadministration of articaine with oxidizing agents, such as 
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely 
for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue articaine and any other oxidizing agents. 
Depending on the severity of symptoms, patients may respond to supportive care; more severe 
symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [28996]
Asenapine: (Major) Avoid coadministration of chloroquine with asenapine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Asenapine has also been associated with QT prolongation. [28229]
[28230] [28231] [29758] [36343] [65157] [65170]
Aspirin, ASA; Citric Acid; Sodium Bicarbonate: (Major) Chloroquine absorption may be reduced 
by antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Atomoxetine: (Major) Avoid coadministration of chloroquine with atomoxetine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. QT prolongation has occurred during therapeutic use of 
atomoxetine and following overdose. [28229] [28230] [28231] [28405] [29758] [59321] [65157] [65170]
Atropine; Hyoscyamine; Phenobarbital; Scopolamine: (Moderate) Coadministration of 
chloroquine and phenobarbital may decrease exposure of chloroquine which may reduce its 
efficacy. Chloroquine may be an in vitro CYP3A4 substrate and phenobarbital is a strong 
CYP3A4 inducer. [65210] [65237] [65239]
Azithromycin: (Major) Avoid coadministration of chloroquine with azithromycin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances (See Therapeutic Drug 
Monitoring for recommendations specific to COVID-19). Chloroquine is associated with an 
increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. QT prolongation and torsade de pointes (TdP) have been 
spontaneously reported during azithromycin postmarketing surveillance. [28229] [28230] [28231]
[28855] [29758] [43974] [65157] [65170]
Bedaquiline: (Major) Avoid coadministration of chloroquine with bedaquiline due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Discontinue bedaquiline if evidence of 
serious ventricular arrhythmia or QTcF interval greater than 500 msec. Bedaquiline prolongs the 
QT interval. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229]
[28230] [28231] [29758] [52746] [65157] [65170]
Belladonna Alkaloids; Ergotamine; Phenobarbital: (Moderate) Coadministration of chloroquine 
and phenobarbital may decrease exposure of chloroquine which may reduce its efficacy. 
Chloroquine may be an in vitro CYP3A4 substrate and phenobarbital is a strong CYP3A4 inducer. 
[65210] [65237] [65239]
Betrixaban: (Moderate) Use caution if chloroquine is coadministered with betrixaban due to the 
potential for increased betrixaban exposure which may increase the risk of bleeding. Betrixaban is 
a P-gp substrate; limited data suggests that chloroquine is a P-gp inhibitor. [62037] [65210]
Bismuth Subcitrate Potassium; Metronidazole; Tetracycline: (Major) Avoid coadministration of 
chloroquine with metronidazole due to the increased risk of QT prolongation. If use together is 
necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Potential 
QT prolongation has been reported in limited case reports with metronidazole. [28229] [28230]
[28231] [29758] [57377] [57378] [65157] [65170]
Bismuth Subsalicylate; Metronidazole; Tetracycline: (Major) Avoid coadministration of 
chloroquine with metronidazole due to the increased risk of QT prolongation. If use together is 
necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Potential 
QT prolongation has been reported in limited case reports with metronidazole. [28229] [28230]
[28231] [29758] [57377] [57378] [65157] [65170]
Budesonide; Formoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Bupivacaine Liposomal: (Moderate) Coadministration of bupivacaine with oxidizing agents, such 
as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely 
for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue bupivacaine and any other oxidizing 
agents. Depending on the severity of symptoms, patients may respond to supportive care; more 
severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [52331]
Bupivacaine: (Moderate) Coadministration of bupivacaine with oxidizing agents, such as 
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely 
for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue bupivacaine and any other oxidizing 
agents. Depending on the severity of symptoms, patients may respond to supportive care; more 
severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [52331]
Bupivacaine; Lidocaine: (Moderate) Coadministration of bupivacaine with oxidizing agents, such 
as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely 
for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue bupivacaine and any other oxidizing 
agents. Depending on the severity of symptoms, patients may respond to supportive care; more 
severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [52331] (Moderate) Coadministration of lidocaine with oxidizing agents, such as 
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely 
for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue lidocaine and any other oxidizing agents. 
Depending on the severity of symptoms, patients may respond to supportive care; more severe 
symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [43383]
Buprenorphine: (Major) Avoid coadministration of chloroquine with buprenorphine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Buprenorphine has been associated with QT 
prolongation and has a possible risk of TdP. [28229] [28230] [28231] [29758] [41235] [59321] [60270]
[65157] [65170]
Buprenorphine; Naloxone: (Major) Avoid coadministration of chloroquine with buprenorphine 
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at 
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Buprenorphine has been associated with 
QT prolongation and has a possible risk of TdP. [28229] [28230] [28231] [29758] [41235] [59321]
[60270] [65157] [65170]
Calcium Carbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer 
chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Calcium Carbonate; Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced by 
antacids. Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
(Major) Chloroquine absorption may be reduced by antacids. Administer chloroquine and antacids 
at least 4 hours apart. [29758] [30285]
Calcium Carbonate; Risedronate: (Major) Chloroquine absorption may be reduced by antacids. 
Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Calcium Carbonate; Simethicone: (Major) Chloroquine absorption may be reduced by antacids. 
Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Canagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Canagliflozin; Metformin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Carbamazepine: (Moderate) Coadministration of chloroquine and carbamazepine may decrease 
exposure of chloroquine which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 
substrate and carbamazepine is a strong CYP3A4 inducer. [65210] [65237] [65239]
Ceritinib: (Major) Avoid coadministration of chloroquine with ceritinib due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Interrupt, dose reduce, or discontinue 
ceritinib if QT prolongation occurs. Ceritinib causes concentration-dependent QT prolongation. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28230] [28231]
[29758] [34353] [57094] [65157] [65170]
Chloroprocaine: (Moderate) Coadministration of chloroprocaine with oxidizing agents, such as 
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely 
for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue chloroprocaine and any other oxidizing 
agents. Depending on the severity of symptoms, patients may respond to supportive care; more 
severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [29062]
Chlorpromazine: (Major) Avoid coadministration of chloroquine with chlorpromazine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Chlorpromazine is associated with an established risk of 
QT prolongation and TdP. [28229] [28230] [28231] [29758] [43065] [59321] [65157] [65170]
Chlorpropamide: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Cimetidine: (Major) Avoid concomitant use of chloroquine and cimetidine as cimetidine may 
inhibit the metabolism of chloroquine, increasing its plasma concentration. [29758] [34335] [34353]
[61759] [61760]
Ciprofloxacin: (Major) Avoid coadministration of chloroquine with ciprofloxacin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Rare cases of QT prolongation and TdP have been 
reported with ciprofloxacin during postmarketing surveillance. [28229] [28230] [28231] [29758]
[43411] [46655] [65157] [65170]
Cisapride: (Severe) Coadministration of chloroquine with cisapride is contraindicated due to the 
increased risk of QT prolongation. Chloroquine is associated with an increased risk of QT 
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher 
chloroquine doses. QT prolongation and ventricular arrhythmias, including TdP and death, have 
been reported with cisapride. [28229] [28230] [28231] [29758] [47221] [65157] [65170]
Citalopram: (Major) Avoid coadministration of chloroquine with citalopram due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Citalopram causes dose-dependent QT interval prolongation. 
[28229] [28230] [28231] [28269] [29758] [65157] [65170]
Clarithromycin: (Major) Avoid coadministration of chloroquine with clarithromycin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Clarithromycin is associated with an established risk for 
QT prolongation and TdP. [28229] [28230] [28231] [28238] [29758] [59321] [65157] [65170]
Clofazimine: (Major) Avoid coadministration of chloroquine with clofazimine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. QT prolongation and TdP have been reported in patients receiving 
clofazimine in combination with QT prolonging medications. [28229] [28230] [28231] [29758]
[63936] [65157] [65170]
Clomipramine: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants 
(TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. TCAs share pharmacologic properties 
similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in 
overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Clozapine: (Major) Avoid coadministration of chloroquine with clozapine due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Treatment with clozapine has been associated with QT 
prolongation, TdP, cardiac arrest, and sudden death. [28229] [28230] [28231] [28262] [29758] [65157]
[65170]
Cobimetinib: (Moderate) Concurrent use of chloroquine and cobimetinib is not recommended as 
there is an increased risk of retinal toxicity. [29758] [60281]
Codeine; Phenylephrine; Promethazine: (Major) Avoid coadministration of chloroquine with 
promethazine due to the increased risk of QT prolongation. If use together is necessary, obtain an 
ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG 
monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. Promethazine is associated 
with a possible risk for QT prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157]
[65170]
Codeine; Promethazine: (Major) Avoid coadministration of chloroquine with promethazine due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Promethazine is associated with a possible risk for QT 
prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170]
Crizotinib: (Major) Avoid coadministration of chloroquine with crizotinib due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. An interruption of therapy, dose reduction, 
or discontinuation of therapy may be necessary for crizotinib if QT prolongation occurs. 
Crizotinib can cause concentration-dependent QT prolongation. Chloroquine is associated with an 
increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. [28229] [28231] [29758] [45458] [65157] [65170]
Cyclosporine: (Major) Close monitoring of serum cyclosporine concentrations is recommended 
during coadministration of chloroquine. Sudden increases in cyclosporine concentrations have 
been reported after the addition of chloroquine. Discontinue chloroquine if necessary. [29758]
Dabigatran: (Moderate) Use caution if chloroquine is coadministered with dabigatran due to the 
potential for increased dabigatran exposure which may increase the risk of bleeding. Dabigatran is 
a P-gp substrate; limited data suggests that chloroquine is a P-gp inhibitor. [42121] [65210]
Dapagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Dapagliflozin; Metformin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Dapagliflozin; Saxagliptin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are 
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe 
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an 
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Dapsone: (Moderate) Coadministration of dapsone with chloroquine may increase the risk of 
developing methemoglobinemia. Advise patients to discontinue treatment and seek immediate 
medical attention with any signs or symptoms of methemoglobinemia. [60612]
Dasatinib: (Major) Avoid coadministration of chloroquine with dasatinib due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. In vitro studies have shown that dasatinib has the potential to 
prolong the QT interval. [28229] [28230] [28231] [29758] [32387] [65157] [65170]
Degarelix: (Major) Avoid coadministration of chloroquine with degarelix due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Androgen deprivation therapy (i.e., degarelix) may also prolong 
the QT/QTc interval. [28229] [28230] [28231] [29758] [46869] [65157] [65170]
Desflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Halogenated anesthetics are known to prolong the QT 
interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] [59321] [65157]
[65170]
Desipramine: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants 
(TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. TCAs share pharmacologic properties 
similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in 
overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Deutetrabenazine: (Major) Avoid coadministration of chloroquine with deutetrabenazine due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. For patients taking a 
deutetrabenazine dosage more than 24 mg/day, assess the QTc interval before and after increasing 
the deutetrabenazine dosage or other medications that prolong the QTc interval. Clinically relevant 
QTc prolongation may occur with deutetrabenazine. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. [28229] [28230] [28231] [29758] [61845] [65157] [65170]
Dextromethorphan; Promethazine: (Major) Avoid coadministration of chloroquine with 
promethazine due to the increased risk of QT prolongation. If use together is necessary, obtain an 
ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG 
monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. Promethazine is associated 
with a possible risk for QT prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157]
[65170]
Dextromethorphan; Quinidine: (Major) Avoid coadministration of chloroquine with quinidine due 
to the increased risk of QT prolongation or other drug toxicities. If use together is necessary, 
obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent 
ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Quinidine 
administration is also associated with QT prolongation and TdP. [28229] [28230] [28231] [29758]
[42280] [47357] [65157] [65170]
Digoxin: (Moderate) Monitor serum digoxin concentrations in patients receiving digoxin and 
chloroquine as coadministration may result in increased serum digoxin concentrations. Digoxin 
serum concentrations have been reported to increase when hydroxychloroquine was added. 
Although this interaction has not been reported with chloroquine, chloroquine may similarly 
increase the plasma concentration of digoxin. [41806] [60957]
Dipeptidyl Peptidase-4 Inhibitors: (Major) Careful monitoring of blood glucose is recommended 
when chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are 
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe 
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an 
antidiabetic agent. [29758]
Disopyramide: (Major) Avoid coadministration of chloroquine with disopyramide due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Disopyramide administration is associated with QT 
prolongation and TdP. [28228] [28229] [28230] [28231] [29758] [65157] [65170]
Dofetilide: (Major) Avoid coadministration of chloroquine with dofetilide due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Dofetilide, a Class III antiarrhythmic agent, is associated with a 
well-established risk of QT prolongation and TdP. [28221] [28229] [28230] [28231] [28432] [28457]
[29758] [65157] [65170]
Dolasetron: (Major) Avoid coadministration of chloroquine with dolasetron due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Dolasetron has been associated with a dose-dependent 
prolongation of the QT, PR, and QRS intervals on an electrocardiogram. [28229] [28230] [28231]
[29758] [34353] [42844] [55935] [65157] [65170]
Dolutegravir; Rilpivirine: (Major) Avoid coadministration of chloroquine with rilpivirine due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) 
have caused QT prolongation. [28229] [28230] [28231] [29758] [44376] [65157] [65170]
Donepezil: (Major) Avoid coadministration of chloroquine with donepezil due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Case reports indicate that QT prolongation and TdP can occur 
during donepezil therapy. [28229] [28230] [28231] [29758] [59321] [59322] [65157] [65170]
Donepezil; Memantine: (Major) Avoid coadministration of chloroquine with donepezil due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Case reports indicate that QT prolongation and TdP can 
occur during donepezil therapy. [28229] [28230] [28231] [29758] [59321] [59322] [65157] [65170]
Doxepin: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) 
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at 
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. TCAs share pharmacologic properties 
similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in 
overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Dronedarone: (Severe) Coadministration of chloroquine with dronedarone is contraindicated due 
to the increased risk of QT prolongation. Dronedarone administration is associated with a dose-
related increase in the QTc interval. The increase in QTc is approximately 10 milliseconds at doses 
of 400 mg twice daily (the FDA-approved dose) and up to 25 milliseconds at doses of 1,600 mg 
twice daily. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. [28229]
[28230] [28231] [29758] [36101] [65157] [65170]
Droperidol: (Major) Avoid coadministration of chloroquine with droperidol due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Initiate droperidol at a low dose and increase 
the dose as needed to achieve the desired effect. Droperidol administration is associated with an 
established risk for QT prolongation and torsade de pointes (TdP). Some cases have occurred in 
patients with no known risk factors for QT prolongation and some cases have been fatal. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28231] [28235]
[28236] [28237] [28737] [29758] [51289] [59321] [65157] [65170]
Dulaglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Edoxaban: (Moderate) Use caution if chloroquine is coadministered with edoxaban due to the 
potential for increased edoxaban exposure which may increase the risk of bleeding. Edoxaban is a 
P-gp substrate; limited data suggests that chloroquine is a P-gp inhibitor. [58685] [65210]
Efavirenz: (Major) Avoid coadministration of chloroquine with efavirenz due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. QTc prolongation has been observed with the use of efavirenz. 
[28229] [28230] [28231] [28442] [29758] [65157] [65170]
Efavirenz; Emtricitabine; Tenofovir: (Major) Avoid coadministration of chloroquine with 
efavirenz due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. QTc prolongation has been observed 
with the use of efavirenz. [28229] [28230] [28231] [28442] [29758] [65157] [65170]
Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of 
chloroquine with efavirenz due to the increased risk of QT prolongation. If use together is 
necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. QTc 
prolongation has been observed with the use of efavirenz. [28229] [28230] [28231] [28442] [29758]
[65157] [65170]
Eliglustat: (Major) Avoid coadministration of chloroquine with eliglustat due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Eliglustat is predicted to cause PR, QRS, and/or QT prolongation 
at significantly elevated plasma concentrations. [28229] [28230] [28231] [29758] [57803] [65157]
[65170]
Empagliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Empagliflozin; Linagliptin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are 
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe 
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an 
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Empagliflozin; Linagliptin; Metformin: (Major) Careful monitoring of blood glucose is 
recommended when chloroquine and antidiabetic agents, including metformin, are 
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe 
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an 
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are 
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe 
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an 
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Empagliflozin; Metformin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Emtricitabine; Rilpivirine; Tenofovir alafenamide: (Major) Avoid coadministration of chloroquine 
with rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an 
ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG 
monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. Supratherapeutic doses of 
rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229] [28230] [28231] [29758] [44376]
[65157] [65170]
Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: (Major) Avoid coadministration of 
chloroquine with rilpivirine due to the increased risk of QT prolongation. If use together is 
necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. 
Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [28229]
[28230] [28231] [29758] [44376] [65157] [65170]
Encorafenib: (Major) Avoid coadministration of chloroquine with encorafenib due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Encorafenib has been associated with dose-dependent QT 
prolongation. [28229] [28230] [28231] [29758] [63317] [65157] [65170]
Enflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Halogenated anesthetics are known to prolong the QT 
interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] [59321] [65157]
[65170]
Entrectinib: (Major) Avoid coadministration of chloroquine with entrectinib due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Entrectinib has been associated with QT prolongation. [28229]
[28230] [28231] [29758] [64567] [65157] [65170]
Eribulin: (Major) Avoid coadministration of chloroquine with eribulin due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Eribulin has been associated with QT prolongation. [28229] [28230]
[28231] [29758] [42449] [65157] [65170]
Ertugliflozin: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Ertugliflozin; Metformin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the SGLT2 inhibitors, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Ertugliflozin; Sitagliptin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are 
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe 
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an 
antidiabetic agent. [29758] (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Erythromycin: (Major) Avoid coadministration of chloroquine with erythromycin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Erythromycin is associated with QT prolongation and 
TdP. [28229] [28230] [28231] [29758] [43258] [59321] [65157] [65170]
Erythromycin; Sulfisoxazole: (Major) Avoid coadministration of chloroquine with erythromycin 
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at 
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Erythromycin is associated with QT 
prolongation and TdP. [28229] [28230] [28231] [29758] [43258] [59321] [65157] [65170]
Escitalopram: (Major) Avoid coadministration of chloroquine with escitalopram due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Escitalopram has been associated with a risk of QT 
prolongation and TdP. [28229] [28230] [28231] [28270] [29758] [65157] [65170]
Exenatide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Ezogabine: (Major) Avoid coadministration of chloroquine with ezogabine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Ezogabine has been associated with QT prolongation. [28229]
[28230] [28231] [29758] [44800] [65157] [65170]
Fingolimod: (Major) Avoid coadministration of chloroquine with fingolimod due to the increased 
risk of QT prolongation. If use together is necessary, overnight monitoring with continuous ECG 
in a medical facility is advised after the first dose of fingolimod; monitor ECG closely throughout 
therapy, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. Fingolimod initiation 
results in decreased heart rate and may prolong the QT interval. Fingolimod has not been studied 
in patients treated with drugs that prolong the QT interval, but drugs that prolong the QT interval 
have been associated with cases of TdP in patients with bradycardia. [28229] [28230] [28231] [29758]
[65157] [65170]
Flecainide: (Major) Avoid coadministration of chloroquine with flecainide due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Flecainide is a Class IC antiarrhythmic associated with a possible 
risk for QT prolongation and/or TdP; flecainide increases the QT interval, but largely due to 
prolongation of the QRS interval. Although causality for TdP has not been established for 
flecainide, patients receiving concurrent drugs that have the potential for QT prolongation may 
have an increased risk of developing proarrhythmias. [23774] [28229] [28230] [28231] [28752] [29758]
[51070] [65157] [65170]
Fluconazole: (Major) Avoid coadministration of chloroquine with fluconazole due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Fluconazole has been associated with QT prolongation and rare 
cases of TdP. [28229] [28230] [28231] [28674] [29758] [60686] [65157] [65170]
Fluoxetine: (Major) Avoid coadministration of chloroquine with fluoxetine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. QT prolongation and TdP have been reported in patients treated 
with fluoxetine. [28229] [28230] [28231] [29758] [32127] [44058] [44059] [65157] [65170]
Fluoxetine; Olanzapine: (Major) Avoid coadministration of chloroquine with fluoxetine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. QT prolongation and TdP have been reported in patients 
treated with fluoxetine. [28229] [28230] [28231] [29758] [32127] [44058] [44059] [65157] [65170]
(Major) Avoid coadministration of chloroquine with olanzapine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging 
drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT 
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher 
chloroquine doses. Limited data, including some case reports, suggest that olanzapine may be 
associated with a significant prolongation of the QTc interval. [28229] [28230] [28231] [28785]
[29758] [32732] [32734] [32745] [65157] [65170]
Fluphenazine: (Major) Avoid coadministration of chloroquine with fluphenazine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Fluphenazine is associated with a possible risk for QT 
prolongation. [28229] [28230] [28231] [28415] [29758] [59321] [65157] [65170]
Fluticasone; Salmeterol: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Fluticasone; Umeclidinium; Vilanterol: (Major) Avoid coadministration of chloroquine with long-
acting beta-agonists due to the increased risk of QT prolongation. If use together is necessary, 
obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent 
ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Beta-
agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other 
drugs known to prolong the QT interval. This risk may be more clinically significant with long-
acting beta-agonists (LABAs) as compared to short-acting beta-agonists.. [28229] [29758] [41231]
[44026] [44063] [44979] [59321] [65157] [65170]
Fluticasone; Vilanterol: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Fluvoxamine: (Major) Avoid coadministration of chloroquine with fluvoxamine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. QT prolongation and TdP has been reported during 
fluvoxamine postmarketing use. [28229] [28230] [28231] [29758] [50507] [65157] [65170]
Formoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Beta-agonists may be associated with adverse 
cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Formoterol; Mometasone: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Foscarnet: (Major) Avoid coadministration of chloroquine with foscarnet due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Both QT prolongation and TdP have been reported during 
postmarketing use of foscarnet. [28229] [28230] [28231] [28377] [29758] [65157] [65170]
Gemifloxacin: (Major) Avoid coadministration of chloroquine with gemifloxacin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Gemifloxacin may prolong the QT interval in some 
patients. The maximal change in the QTc interval occurs approximately 5 to 10 hours following 
oral administration of gemifloxacin. The likelihood of QTc prolongation may increase with 
increasing gemifloxacin dose; therefore, do not exceed the recommended dose, especially in 
patients with renal or hepatic impairment where the Cmax and AUC are slightly higher. [28229]
[28230] [28231] [28419] [28420] [28424] [29758] [65157] [65170]
Gemtuzumab Ozogamicin: (Major) Avoid coadministration of chloroquine with gemtuzumab due 
to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Although QT interval prolongation has not been reported 
with gemtuzumab, it has been reported with other drugs that contain calicheamicin. [28229] [28230]
[28231] [29758] [62292] [65157] [65170]
Gilteritinib: (Major) Avoid coadministration of chloroquine with gilteritinib due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Gilteritinib has been associated with QT prolongation. [28229]
[28230] [28231] [29758] [63787] [65157] [65170]
Glasdegib: (Major) Avoid coadministration of chloroquine with glasdegib due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Glasdegib therapy may result in QT prolongation and ventricular 
arrhythmias including ventricular fibrillation and ventricular tachycardia. [28229] [28230] [28231]
[29758] [63777] [65157] [65170]
Glimepiride: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Glimepiride; Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased 
dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in 
patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Glimepiride; Rosiglitazone: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased 
dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in 
patients treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Glipizide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Glipizide; Metformin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be necessary 
as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and 
an antidiabetic agent. [29758]
Glyburide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Glyburide; Metformin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the sulfonylureas, are coadministered. A decreased dose of the antidiabetic agent may be necessary 
as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and 
an antidiabetic agent. [29758]
Glycopyrrolate; Formoterol: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Goserelin: (Major) Avoid coadministration of chloroquine with goserelin due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Androgen deprivation therapy (i.e., goserelin) may also prolong the 
QT/QTc interval. [28229] [28230] [28231] [28592] [29758] [65157] [65170]
Granisetron: (Major) Avoid coadministration of chloroquine with granisetron due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Granisetron has been associated with QT prolongation. [28229]
[28230] [28231] [29758] [31723] [65157] [65170]
Halogenated Anesthetics: (Major) Avoid coadministration of chloroquine with halogenated 
anesthetics due to the increased risk of QT prolongation. If use together is necessary, obtain an 
ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG 
monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. Halogenated anesthetics 
are known to prolong the QT interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756]
[29758] [59321] [65157] [65170]
Haloperidol: (Major) Avoid coadministration of chloroquine with haloperidol due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. QT prolongation and TdP have been observed during haloperidol 
treatment. Excessive doses (particularly in the overdose setting) or IV administration of 
haloperidol may be associated with a higher risk of QT prolongation. [23500] [23779] [28229]
[28230] [28231] [28307] [28415] [29758] [59321] [65157] [65170]
Halothane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Halogenated anesthetics are known to prolong the QT 
interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] [59321] [65157]
[65170]
Histrelin: (Major) Avoid coadministration of chloroquine with histrelin due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Androgen deprivation therapy (i.e., histrelin) may prolong the 
QT/QTc interval. [28229] [28230] [28231] [29758] [30369] [65157] [65170]
Hydroxyzine: (Major) Avoid coadministration of chloroquine with hydroxyzine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Postmarketing data indicate that hydroxyzine causes QT 
prolongation and TdP. [28229] [28230] [28231] [29758] [47129] [61470] [65157] [65170]
Ibutilide: (Major) Avoid coadministration of chloroquine with ibutilide due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Ibutilide administration can cause QT prolongation and TdP; 
proarrhythmic events should be anticipated. The potential for proarrhythmic events with ibutilide 
increases with the use of other drugs that prolong the QT interval. [28229] [28230] [28231] [29758]
[41830] [65157] [65170]
Iloperidone: (Major) Avoid coadministration of chloroquine with iloperidone due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Iloperidone has also been associated with QT prolongation. [28229]
[28230] [28231] [29758] [36146] [65157] [65170]
Imipramine: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) 
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at 
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. TCAs share pharmacologic properties 
similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in 
overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Incretin Mimetics: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the incretin mimetics, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Indacaterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Beta-agonists may be associated with adverse 
cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Indacaterol; Glycopyrrolate: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Inotuzumab Ozogamicin: (Major) Avoid coadministration of chloroquine with inotuzumab due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Inotuzumab has also been associated with QT interval 
prolongation. [28229] [28230] [28231] [29758] [62245] [65157] [65170]
Insulin Aspart: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Insulin Aspart; Insulin Aspart Protamine: (Major) Careful monitoring of blood glucose is 
recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Insulin Degludec: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Insulin Degludec; Liraglutide: (Major) Careful monitoring of blood glucose is recommended 
when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose 
of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Insulin Detemir: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Insulin Glargine: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Insulin Glargine; Lixisenatide: (Major) Careful monitoring of blood glucose is recommended 
when chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose 
of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the incretin mimetics, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Insulin Glulisine: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Insulin Lispro: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Insulin Lispro; Insulin Lispro Protamine: (Major) Careful monitoring of blood glucose is 
recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Insulin, Inhaled: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Insulins: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Interferon Alfa-2a: (Moderate) Concurrent use of chloroquine and interferons is not recommended 
as there is an increased risk of retinal toxicity. [29758] [47391]
Interferon Alfa-2b: (Moderate) Concurrent use of chloroquine and interferons is not recommended 
as there is an increased risk of retinal toxicity. [29758] [47391]
Interferon Alfa-2b; Ribavirin: (Moderate) Concurrent use of chloroquine and interferons is not 
recommended as there is an increased risk of retinal toxicity. [29758] [47391]
Interferon Alfacon-1: (Moderate) Concurrent use of chloroquine and interferons is not 
recommended as there is an increased risk of retinal toxicity. [29758] [47391]
Interferon Alfa-n3: (Moderate) Concurrent use of chloroquine and interferons is not recommended 
as there is an increased risk of retinal toxicity. [29758] [47391]
Interferon Beta-1a: (Moderate) Concurrent use of chloroquine and interferons is not recommended 
as there is an increased risk of retinal toxicity. [29758] [47391]
Interferon Beta-1b: (Moderate) Concurrent use of chloroquine and interferons is not recommended 
as there is an increased risk of retinal toxicity. [29758] [47391]
Interferon Gamma-1b: (Moderate) Concurrent use of chloroquine and interferons is not 
recommended as there is an increased risk of retinal toxicity. [29758] [47391]
Interferons: (Moderate) Concurrent use of chloroquine and interferons is not recommended as 
there is an increased risk of retinal toxicity. [29758] [47391]
Isoflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Halogenated anesthetics are known to prolong the QT 
interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] [59321] [65157]
[65170]
Isophane Insulin (NPH): (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Itraconazole: (Major) Avoid coadministration of chloroquine with itraconazole due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Itraconazole has also been associated with prolongation 
of the QT interval. [27983] [28229] [28230] [28231] [29758] [40233] [57441] [63821] [65157] [65170]
Ivosidenib: (Major) Avoid coadministration of chloroquine with ivosidenib due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. An interruption of therapy and dose 
reduction of ivosidenib may be necessary if QT prolongation occurs. Prolongation of the QTc 
interval and ventricular arrhythmias have been reported in patients treated with ivosidenib. 
Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); 
the risk of QT prolongation is increased with higher chloroquine doses. [28229] [28230] [28231]
[29758] [65157] [65170]
Ketoconazole: (Major) Avoid coadministration of chloroquine with systemic ketoconazole due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Ketoconazole has been associated with prolongation of 
the QT interval. [27982] [28229] [28230] [28231] [29758] [59321] [65157] [65170]
Lanthanum Carbonate: (Major) Oral compounds known to interact with antacids, like chloroquine, 
should not be taken within 4 hours of dosing with lanthanum carbonate. If these agents are used 
concomitantly, space the dosing intervals appropriately. Monitor serum concentrations and clinical 
condition. [29758] [30284] [30285] [44406]
Lapatinib: (Major) Avoid coadministration of chloroquine with lapatinib due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Lapatinib has been associated with concentration-dependent QT 
prolongation; ventricular arrhythmias and TdP have been reported in postmarketing experience 
with lapatinib. [28229] [28230] [28231] [29758] [33192] [65157] [65170]
Lefamulin: (Major) Avoid coadministration of chloroquine with lefamulin due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Lefamulin has a concentration dependent QTc prolongation effect. 
The potential to prolong the QT interval of the ECG between lefamulin and other drugs that effect 
cardiac conduction is unknown. [28229] [28230] [28231] [29758] [64576] [65157] [65170]
Lente Insulin: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Lenvatinib: (Major) Avoid coadministration of chloroquine with lenvatinib due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Prolongation of the QT interval has been reported with lenvatinib 
therapy. [28229] [28230] [28231] [29758] [58782] [65157] [65170]
Leuprolide: (Major) Avoid coadministration of chloroquine with leuprolide due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Androgen deprivation therapy (i.e., leuprolide) may prolong the 
QT/QTc interval. [28229] [28230] [28231] [29758] [43800] [65157] [65170]
Leuprolide; Norethindrone: (Major) Avoid coadministration of chloroquine with leuprolide due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Androgen deprivation therapy (i.e., leuprolide) may 
prolong the QT/QTc interval. [28229] [28230] [28231] [29758] [43800] [65157] [65170]
Levalbuterol: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due 
to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Beta-agonists may be associated with adverse 
cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists as compared to short-
acting beta-agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Levofloxacin: (Major) Avoid coadministration of chloroquine with levofloxacin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Levofloxacin has been associated with prolongation of 
the QT interval and infrequent cases of arrhythmia. Additionally, rare cases of TdP have been 
spontaneously reported during postmarketing surveillance in patients receiving levofloxacin. 
[28229] [28230] [28231] [28421] [29758] [61195] [63729] [65157] [65170]
Lidocaine: (Moderate) Coadministration of lidocaine with oxidizing agents, such as chloroquine, 
may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and 
symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs 
or is suspected, discontinue lidocaine and any other oxidizing agents. Depending on the severity of 
symptoms, patients may respond to supportive care; more severe symptoms may require treatment 
with methylene blue, exchange transfusion, or hyperbaric oxygen. [43383]
Linagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Linagliptin; Metformin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Liraglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Lithium: (Major) Avoid coadministration of chloroquine with lithium due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Lithium has also been associated with QT prolongation. [28229]
[28230] [28231] [29758] [59809] [59810] [59811] [65157] [65170]
Lixisenatide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Lofexidine: (Major) Avoid coadministration of chloroquine with lofexidine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Lofexidine also prolongs the QT interval. [28229] [28230] [28231]
[29758] [63161] [65157] [65170]
Lomefloxacin: (Major) Avoid coadministration of chloroquine with lomefloxacin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Cases of QT prolongation and TdP have been reported 
with lomefloxacin. [29758] [29948] [59321]
Long-acting beta-agonists: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Loperamide: (Major) Avoid coadministration of chloroquine with loperamide due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. At high doses, loperamide has been associated with serious cardiac 
toxicities, including syncope, ventricular tachycardia, QT prolongation,TdP, and cardiac arrest. 
[28229] [28230] [28231] [29758] [30106] [60864] [65157] [65170]
Loperamide; Simethicone: (Major) Avoid coadministration of chloroquine with loperamide due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. At high doses, loperamide has been associated with 
serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation,TdP, and 
cardiac arrest. [28229] [28230] [28231] [29758] [30106] [60864] [65157] [65170]
Lopinavir; Ritonavir: (Major) Avoid coadministration of chloroquine and lopinavir due the risk of 
additive QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); fatalities have been reported. The risk of QT 
prolongation is increased with higher chloroquine doses. Lopinavir is also associated with QT 
prolongation. [28229] [28230] [28231] [28341] [29758] [65157] [65170]
Macimorelin: (Major) Avoid coadministration of chloroquine with macimorelin due to the 
increased risk of QT prolongation and torsade de pointes-type ventricular tachycardia. Allow a 
sufficient washout period before starting macimorelin. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Treatment with macimorelin has been 
associated with an increase in the corrected QT (QTc) interval. [28229] [28230] [28231] [29758]
[62723] [65157] [65170]
Magnesium Hydroxide: (Major) Chloroquine absorption may be reduced by antacids. Administer 
chloroquine and antacids at least 4 hours apart. [29758] [30285]
Maprotiline: (Major) Avoid coadministration of chloroquine with maprotiline due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Maprotiline has been reported to prolong the QT interval, 
particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). 
Cases of long QT syndrome and TdP tachycardia have been described with maprotiline use, but 
rarely occur when the drug is used alone in normal prescribed doses and in the absence of other 
known risk factors for QT prolongation. Limited data are available regarding the safety of 
maprotiline in combination with other QT-prolonging drugs. [28225] [28229] [28230] [28231] [29758]
[51740] [65157] [65170]
Mefloquine: (Major) Avoid coadministration of chloroquine with mefloquine due to the increased 
risk of QT prolongation and seizures. These drugs are both analogs of quinine. If use together is 
necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. There is 
evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QTc 
interval. Mefloquine alone has not been reported to cause QT prolongation. Also, both drugs may 
lower the seizure threshold. [28229] [28230] [28231] [28301] [29758] [65157] [65170]
Meglitinides: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the meglitinides, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Meperidine; Promethazine: (Major) Avoid coadministration of chloroquine with promethazine due 
to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Promethazine is associated with a possible risk for QT 
prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170]
Mepivacaine: (Moderate) Coadministration of mepivacaine with oxidizing agents, such as 
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely 
for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue mepivacaine and any other oxidizing 
agents. Depending on the severity of symptoms, patients may respond to supportive care; more 
severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [29100]
Mepivacaine; Levonordefrin: (Moderate) Coadministration of mepivacaine with oxidizing agents, 
such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients 
closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue mepivacaine and any other oxidizing 
agents. Depending on the severity of symptoms, patients may respond to supportive care; more 
severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [29100]
Metaproterenol: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists 
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at 
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists as compared to short-
acting beta-agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Metformin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including metformin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Metformin; Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Metformin; Repaglinide: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the meglitinides, are coadministered. A decreased dose of the antidiabetic agent may be necessary 
as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and 
an antidiabetic agent. [29758]
Metformin; Rosiglitazone: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the thiazolidinediones, are coadministered. A decreased dose of the antidiabetic agent may be 
necessary as severe hypoglycemia has been reported in patients treated concomitantly with 
chloroquine and an antidiabetic agent. [29758]
Metformin; Saxagliptin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Metformin; Sitagliptin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including metformin, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758] (Major) Careful 
monitoring of blood glucose is recommended when chloroquine and antidiabetic agents, including 
the dipeptidyl peptidase-4 inhibitors, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Methadone: (Major) Avoid coadministration of chloroquine with methadone due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Methadone is considered to be associated with an increased risk 
for QT prolongation and TdP, especially at higher doses (more than 200 mg/day but averaging 
approximately 400 mg/day in adult patients). Most cases involve patients being treated for pain 
with large, multiple daily doses of methadone, although cases have been reported in patients 
receiving doses commonly used for maintenance treatment of opioid addiction. [28229] [28230]
[28231] [28319] [28320] [28321] [28322] [29758] [33136] [65157] [65170]
Metronidazole: (Major) Avoid coadministration of chloroquine with metronidazole due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Potential QT prolongation has been reported in limited 
case reports with metronidazole. [28229] [28230] [28231] [29758] [57377] [57378] [65157] [65170]
Midostaurin: (Major) Avoid coadministration of chloroquine with midostaurin due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. QT prolongation was reported in patients who received 
midostaurin in clinical trials. [28229] [28230] [28231] [29758] [61906] [65157] [65170]
Mifepristone: (Major) Avoid coadministration of chloroquine with mifepristone due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Mifepristone is associated with dose-related 
prolongation of the QT interval. [28229] [28230] [28231] [29758] [48697] [65157] [65170]
Miglitol: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the alpha-glucosidase inhibitors, are coadministered. A decreased 
dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in 
patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Mirtazapine: (Major) Avoid coadministration of chloroquine with mirtazapine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Mirtazapine has been associated with dose-dependent prolongation 
of the QT interval. TdP has been reported postmarketing, primarily in overdose or in patients with 
other risk factors for QT prolongation. [28229] [28230] [28231] [29758] [40942] [65157] [65170]
Moxifloxacin: (Major) Avoid coadministration of chloroquine with moxifloxacin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Quinolones have been associated with a risk of QT 
prolongation.TdP has been reported during postmarketing surveillance of moxifloxacin. These 
reports generally involved patients with concurrent medical conditions or concomitant 
medications that may have been contributory. [28229] [28230] [28231] [28423] [29758] [59321] [65157]
[65170]
Nateglinide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the meglitinides, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Nilotinib: (Major) Avoid coadministration of chloroquine with nilotinib due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Sudden death and QT interval prolongation have occurred in 
patients who received nilotinib therapy. [28229] [28230] [28231] [29758] [58766] [65157] [65170]
Norfloxacin: (Major) Avoid coadministration of chloroquine with norfloxacin due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Quinolones have been associated with a risk of QT prolongation 
and torsade de pointes (TdP). Although extremely rare,TdP has been reported during 
postmarketing surveillance of norfloxacin. These reports generally involved patients with 
concurrent medical conditions or concomitant medications that may have been contributory. 
[28225] [28229] [28230] [28231] [28432] [28457] [29758] [29818] [65157] [65170]
Nortriptyline: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants 
(TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. TCAs share pharmacologic properties 
similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in 
overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Octreotide: (Major) Avoid coadministration of chloroquine with octreotide due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Arrhythmias, sinus bradycardia, and conduction disturbances have 
occurred during octreotide therapy. Since bradycardia is a risk factor for development of TdP, the 
potential occurrence of bradycardia during octreotide administration could theoretically increase 
the risk of TdP in patients receiving drugs that prolong the QT interval. [28229] [28230] [28231]
[28432] [29113] [29758] [30624] [64969] [65157] [65170]
Ofloxacin: (Major) Avoid coadministration of chloroquine with ofloxacin due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Quinolones have been associated with a risk of QT prolongation 
and TdP. Although extremely rare, torsade de pointes has been reported during postmarketing 
surveillance of ofloxacin. These reports generally involved patients with concurrent medical 
conditions or concomitant medications that may have been contributory. [28229] [28230] [28231]
[29758] [30738] [65157] [65170]
Olanzapine: (Major) Avoid coadministration of chloroquine with olanzapine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Limited data, including some case reports, suggest that olanzapine 
may be associated with a significant prolongation of the QTc interval. [28229] [28230] [28231]
[28785] [29758] [32732] [32734] [32745] [65157] [65170]
Olodaterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Beta-agonists may be associated with adverse 
cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Omeprazole; Sodium Bicarbonate: (Major) Chloroquine absorption may be reduced by antacids. 
Administer chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Ondansetron: (Major) Avoid coadministration of chloroquine with ondansetron due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Ondansetron has been associated with a dose-related 
increase in the QT interval and postmarketing reports of TdP. [28229] [28230] [28231] [29758]
[31266] [32722] [34335] [34353] [65157] [65170]
Osilodrostat: (Major) Avoid coadministration of chloroquine with osilodrostat due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Osilodrostat is associated with dose-dependent QT prolongation. 
[28229] [28230] [28231] [29758] [65098] [65157] [65170]
Osimertinib: (Major) Avoid coadministration of chloroquine with osimertinib due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. An interruption of osimertinib therapy with 
dose reduction or discontinuation may be necessary if QT prolongation occurs. Concentration-
dependent QTc prolongation occurred during clinical trials of osimertinib. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. [28229] [28230] [28231] [29758] [60297]
[65157] [65170]
Oxaliplatin: (Major) Avoid coadministration of chloroquine with oxaliplatin due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. QT prolongation and ventricular arrhythmias including fatal TdP 
have been reported with oxaliplatin use in postmarketing experience. [28229] [28230] [28231]
[28415] [29758] [41958] [65157] [65170]
Paliperidone: (Major) Avoid coadministration of chloroquine with paliperidone due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Paliperidone has been associated with QT prolongation; 
TdP and ventricular fibrillation have been reported in the setting of overdose. [28229] [28230]
[28231] [29758] [40936] [65157] [65170]
Panobinostat: (Major) Avoid coadministration of chloroquine with panobinostat due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. QT prolongation has also been reported with 
panobinostat. [28229] [28230] [28231] [29758] [58821] [65157] [65170]
Pasireotide: (Major) Avoid coadministration of chloroquine with pasireotide due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. QT prolongation has occurred with pasireotide at therapeutic and 
supra-therapeutic doses. [28229] [28230] [28231] [29758] [65157] [65170]
Pazopanib: (Major) Avoid coadministration of chloroquine with pazopanib due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Pazopanib has also been reported to prolong the QT interval. 
[28229] [28230] [28231] [29758] [37098] [65157] [65170]
Peginterferon Alfa-2a: (Moderate) Concurrent use of chloroquine and interferons is not 
recommended as there is an increased risk of retinal toxicity. [29758] [47391]
Peginterferon Alfa-2b: (Moderate) Concurrent use of chloroquine and interferons is not 
recommended as there is an increased risk of retinal toxicity. [29758] [47391]
Peginterferon beta-1a: (Moderate) Concurrent use of chloroquine and interferons is not 
recommended as there is an increased risk of retinal toxicity. [29758] [47391]
Penicillamine: (Major) Do not use penicillamine concurrently with antimalarials due to an 
increased risk of severe hematologic and renal adverse reactions. [28834]
Penicillin G Benzathine; Penicillin G Procaine: (Moderate) Coadministration of penicillin G 
procaine with oxidizing agents, such as chloroquine, may increase the risk of developing 
methemoglobinemia. Monitor patients closely for signs and symptoms of methemoglobinemia if 
coadministration is necessary. If methemoglobinemia occurs or is suspected, discontinue penicillin 
G procaine and any other oxidizing agents. Depending on the severity of symptoms, patients may 
respond to supportive care; more severe symptoms may require treatment with methylene blue, 
exchange transfusion, or hyperbaric oxygen. [31217]
Penicillin G Procaine: (Moderate) Coadministration of penicillin G procaine with oxidizing 
agents, such as chloroquine, may increase the risk of developing methemoglobinemia. Monitor 
patients closely for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue penicillin G procaine and any other 
oxidizing agents. Depending on the severity of symptoms, patients may respond to supportive 
care; more severe symptoms may require treatment with methylene blue, exchange transfusion, or 
hyperbaric oxygen. [31217]
Pentamidine: (Major) Avoid coadministration of chloroquine with pentamidine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Systemic pentamidine has also been associated with QT 
prolongation. [23620] [23778] [28229] [28230] [28231] [28419] [28879] [29758] [65157] [65170]
Perphenazine: (Major) Avoid coadministration of chloroquine with perphenazine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Perphenazine is associated with a possible risk for QT 
prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170]
Perphenazine; Amitriptyline: (Major) Avoid coadministration of chloroquine with perphenazine 
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at 
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Perphenazine is associated with a 
possible risk for QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170] (Major) 
Avoid coadministration of chloroquine with tricyclic antidepressants (TCAs) due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. TCAs share pharmacologic properties similar to the Class IA 
antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-
dose prescription therapy (elevated serum concentrations). [28225] [28229] [28230] [28231] [28415]
[28416] [29758] [65157] [65170]
Phenobarbital: (Moderate) Coadministration of chloroquine and phenobarbital may decrease 
exposure of chloroquine which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 
substrate and phenobarbital is a strong CYP3A4 inducer. [65210] [65237] [65239]
Phenylephrine; Promethazine: (Major) Avoid coadministration of chloroquine with promethazine 
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at 
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Promethazine is associated with a 
possible risk for QT prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170]
Phenytoin: (Moderate) Coadministration of chloroquine and phenytoin may decrease exposure of 
chloroquine which may reduce its efficacy. Chloroquine may be an in vitro CYP3A4 substrate and 
phenytoin is a strong CYP3A4 inducer. [65210] [65237] [65239]
Pimavanserin: (Major) Avoid coadministration of chloroquine with pimavanserin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Pimavanserin also prolongs the QT interval. [28229]
[28230] [28231] [29758] [60748] [65157] [65170]
Pimozide: (Severe) Coadministration of chloroquine with pimozide is contraindicated due to the 
increased risk of QT prolongation. Chloroquine is associated with an increased risk of QT 
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher 
chloroquine doses. Pimozide is associated with a well-established risk of QT prolongation and 
TdP. [28225] [28229] [28230] [28231] [29758] [43463] [65170]
Pioglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Pirbuterol: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Beta-agonists may be associated with adverse 
cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists as compared to short-
acting beta-agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Pitolisant: (Major) Avoid coadministration of chloroquine with pitolisant due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Pitolisant also prolongs the QT interval. [28229] [28230] [28231]
[29758] [64562] [65157] [65170]
Ponatinib: (Moderate) Concurrent use of chloroquine and ponatinib is not recommended as there 
is an increased risk of retinal toxicity. [29758] [52603]
Posaconazole: (Major) Avoid coadministration of chloroquine with posaconazole due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Posaconazole has been associated with QT prolongation 
and TdP. [28229] [28230] [28231] [29758] [32723] [65157] [65170]
Pramlintide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including pramlintide, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Praziquantel: (Minor) Concomitant administration of chloroquine and praziquantel can reduce 
praziquantel bioavailability and maximum serum concentrations. The mechanism of the 
interaction is not certain. Clinicians should be alert to the possibility of praziquantel failure if 
chloroquine is used. [27846] [29758]
Prilocaine: (Moderate) Coadministration of prilocaine with oxidizing agents, such as chloroquine, 
may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and 
symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs 
or is suspected, discontinue prilocaine and any other oxidizing agents. Depending on the severity 
of symptoms, patients may respond to supportive care; more severe symptoms may require 
treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [29064]
Prilocaine; Epinephrine: (Moderate) Coadministration of prilocaine with oxidizing agents, such as 
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely 
for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue prilocaine and any other oxidizing agents. 
Depending on the severity of symptoms, patients may respond to supportive care; more severe 
symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [29064]
Primaquine: (Major) Avoid coadministration of chloroquine with primaquine due to the increased 
risk of QT prolongation or other toxicities. If use together is necessary, obtain an ECG at baseline 
to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any 
non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated 
with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Primaquine may also prolong the QT 
interval. [28229] [28230] [28231] [29758] [41984] [65157] [65170]
Procainamide: (Major) Avoid coadministration of chloroquine with procainamide due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Procainamide is associated with a well-established risk 
of QT prolongation and TdP. [28229] [28230] [28231] [29758] [65157] [65170]
Prochlorperazine: (Major) Avoid coadministration of chloroquine with prochlorperazine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Prochlorperazine is associated with a possible risk for 
QT prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170]
Promethazine: (Major) Avoid coadministration of chloroquine with promethazine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Promethazine is associated with a possible risk for QT 
prolongation. [28225] [28229] [28230] [28231] [29758] [55578] [65157] [65170]
Propafenone: (Major) Avoid coadministration of chloroquine with propafenone due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Propafenone is a Class IC antiarrhythmic which 
increases the QT interval, but largely due to prolongation of the QRS interval. [28229] [28230]
[28231] [28287] [29758] [65157] [65170]
Protriptyline: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants 
(TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. TCAs share pharmacologic properties 
similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in 
overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Quetiapine: (Major) Avoid coadministration of chloroquine with quetiapine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Limited data, including some case reports, suggest that quetiapine 
may be associated with a significant prolongation of the QTc interval in rare instances. [28229]
[28230] [28231] [29118] [29758] [33068] [33072] [33074] [65157] [65170]
Quinidine: (Major) Avoid coadministration of chloroquine with quinidine due to the increased risk 
of QT prolongation or other drug toxicities. If use together is necessary, obtain an ECG at baseline 
to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any 
non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated 
with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Quinidine administration is also 
associated with QT prolongation and TdP. [28229] [28230] [28231] [29758] [42280] [47357] [65157]
[65170]
Quinine: (Major) Avoid coadministration of chloroquine with quinine due to the increased risk of 
QT prolongation or other drug toxicities. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Quinine has been associated with QT prolongation and 
rare cases of TdP. [28229] [28230] [28231] [29758] [31403] [65157] [65170]
Rabies Vaccine: (Major) If administered concurrently, antimalarials can impair the immunologic 
response to the rabies vaccine, thereby, decreasing its protective effect. If possible, administration 
of antimalarials should be avoided during use of the rabies vaccine for postexposure prophylaxis. 
When antimalarials must be administered to persons also receiving the rabies vaccine for 
postexposure prophylaxis, a serum rabies antibody titer should be obtained on day 14 (day of the 
4th vaccination) to ensure an acceptable antibody response has been induced. [40848] [40849]
Ranolazine: (Major) Avoid coadministration of chloroquine with ranolazine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Ranolazine is associated with dose- and plasma concentration-
related increases in the QTc interval. [28229] [28230] [28231] [29758] [31938] [65157] [65170]
Regular Insulin: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including insulin, are coadministered. A decreased dose of the antidiabetic 
agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Regular Insulin; Isophane Insulin (NPH): (Major) Careful monitoring of blood glucose is 
recommended when chloroquine and antidiabetic agents, including insulin, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Repaglinide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the meglitinides, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Ribociclib: (Major) Avoid coadministration of chloroquine with ribociclib due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Ribociclib has been shown to prolong the QT interval in a 
concentration-dependent manner. [28229] [28230] [28231] [29758] [61816] [65157] [65170]
Ribociclib; Letrozole: (Major) Avoid coadministration of chloroquine with ribociclib due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Ribociclib has been shown to prolong the QT interval in 
a concentration-dependent manner. [28229] [28230] [28231] [29758] [61816] [65157] [65170]
Rilpivirine: (Major) Avoid coadministration of chloroquine with rilpivirine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have 
caused QT prolongation. [28229] [28230] [28231] [29758] [44376] [65157] [65170]
Risperidone: (Major) Avoid coadministration of chloroquine with risperidone due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Risperidone has been associated with a possible risk for QT 
prolongation and/or TdP, primarily in the overdose setting. [22256] [28229] [28414] [29758] [59321]
[65157] [65170]
Romidepsin: (Major) Avoid coadministration of chloroquine with romidepsin due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Romidepsin has been reported to prolong the QT interval. [28229]
[28230] [28231] [29758] [37292] [65157] [65170]
Ropivacaine: (Moderate) Coadministration of ropivacaine with oxidizing agents, such as 
chloroquine, may increase the risk of developing methemoglobinemia. Monitor patients closely 
for signs and symptoms of methemoglobinemia if coadministration is necessary. If 
methemoglobinemia occurs or is suspected, discontinue ropivacaine and any other oxidizing 
agents. Depending on the severity of symptoms, patients may respond to supportive care; more 
severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric 
oxygen. [52330]
Rosiglitazone: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including the thiazolidinediones, are coadministered. A decreased dose of 
the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients 
treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Salmeterol: (Major) Avoid coadministration of chloroquine with long-acting beta-agonists due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Beta-agonists may be associated with adverse 
cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Saquinavir: (Major) Avoid coadministration of chloroquine with saquinavir boosted with ritonavir 
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at 
baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Saquinavir boosted with ritonavir 
increases the QT interval in a dose-dependent fashion, which may increase the risk for serious 
arrhythmias such as TdP. [28229] [28230] [28231] [28995] [29758] [65157] [65170]
Saxagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Semaglutide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the incretin mimetics, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Sertraline: (Major) Avoid coadministration of chloroquine with sertraline due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. The risk of sertraline-induced QT prolongation is generally 
considered to be low in clinical practice. Its effect on QTc interval is minimal (typically less than 5 
msec), and the drug has been used safely in patients with cardiac disease (e.g., recent myocardial 
infarction, unstable angina, chronic heart failure). [28229] [28343] [29758] [64391] [64392] [64394]
[64396] [65157] [65170]
Sevoflurane: (Major) Avoid coadministration of chloroquine with halogenated anesthetics due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Halogenated anesthetics are known to prolong the QT 
interval. [28229] [28230] [28231] [28457] [28458] [28754] [28755] [28756] [29758] [59321] [65157]
[65170]
SGLT2 Inhibitors: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the SGLT2 inhibitors, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Short-acting beta-agonists: (Major) Avoid coadministration of chloroquine with short-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists as compared to short-
acting beta-agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Simvastatin; Sitagliptin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are 
coadministered. A decreased dose of the antidiabetic agent may be necessary as severe 
hypoglycemia has been reported in patients treated concomitantly with chloroquine and an 
antidiabetic agent. [29758]
Siponimod: (Major) Avoid coadministration of chloroquine with siponimod due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Siponimod therapy prolonged the QT interval at recommended 
doses in a clinical study. [28229] [28230] [28231] [29758] [64031] [65157] [65170]
Sitagliptin: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the dipeptidyl peptidase-4 inhibitors, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Sodium Bicarbonate: (Major) Chloroquine absorption may be reduced by antacids. Administer 
chloroquine and antacids at least 4 hours apart. [29758] [30284] [30285]
Solifenacin: (Major) Avoid coadministration of chloroquine with solifenacin due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Solifenacin has been associated with dose-dependent prolongation 
of the QT interval. TdP has been reported with postmarketing use, although causality was not 
determined. [28229] [28230] [28231] [29758] [30515] [65157] [65170]
Sorafenib: (Major) Avoid coadministration of chloroquine with sorafenib due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. An interruption or discontinuation of 
sorafenib therapy may be necessary if QT prolongation occurs. Sorafenib has been associated with 
QT prolongation. Chloroquine is associated with an increased risk of QT prolongation and torsade 
de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses [28229]
[28230] [28231] [29758] [31832] [65157] [65170]
Sotalol: (Major) Avoid coadministration of chloroquine with sotalol due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Sotalol administration is associated with QT prolongation and TdP. 
Proarrhythmic events should be anticipated after initiation of therapy and after each upward 
dosage adjustment. [28229] [28230] [28231] [28234] [29758] [65157] [65170]
Succinylcholine: (Moderate) Chloroquine may enhance the neuromuscular blocking action of 
succinylcholine. [42039]
Sulfonylureas: (Major) Careful monitoring of blood glucose is recommended when chloroquine 
and antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Sunitinib: (Major) Avoid coadministration of chloroquine with sunitinib due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Sunitinib can also prolong the QT interval. [28229] [28230] [28231]
[29758] [65157] [65170]
Tacrolimus: (Major) Avoid coadministration of chloroquine with tacrolimus due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Tacrolimus may prolong the QT interval and cause TdP. [28229]
[28230] [28231] [28611] [29758] [55401] [60497] [65157] [65170]
Tamoxifen: (Major) Avoid coadministration of chloroquine with tamoxifen due to the increased 
risk of QT prolongation and retinal toxicity. If use together is necessary, obtain an ECG at baseline 
to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any 
non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated 
with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Tamoxifen has been reported to prolong 
the QT interval, usually in overdose or when used in high doses. Rare case reports of QT 
prolongation have also been described when tamoxifen is used at lower doses. [28229] [28230]
[28231] [29758] [61872] [63589] [65157] [65170]
Telavancin: (Major) Avoid coadministration of chloroquine with telavancin due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Telavancin has also been associated with QT prolongation. [28229]
[28230] [28231] [29758] [36615] [65157] [65170]
Telbivudine: (Minor) Monitor patients for signs or symptoms of unexplained muscle pain, 
tenderness, or weakness during concomitant treatment with chloroquine and telbivudine. Interrupt 
telbivudine therapy if myopathy is suspected and discontinue telbivudine if myopathy is 
confirmed. It is unknown if the risk of myopathy during treatment with telbivudine is increased 
with coadministration of other drugs associated with myopathy, like chloroquine. [32827]
Telithromycin: (Major) Avoid coadministration of chloroquine with telithromycin due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Telithromycin is also associated with QT prolongation 
and TdP. [28156] [28229] [28230] [28231] [29758] [65157] [65170]
Terbutaline: (Major) Avoid coadministration of chloroquine with short-acting beta-agonists due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Beta-agonists may be associated with adverse 
cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists as compared to short-
acting beta-agonists. [28229] [28532] [29758] [49951] [51793] [59321] [65157] [65170]
Tetrabenazine: (Major) Avoid coadministration of chloroquine with tetrabenazine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Tetrabenazine causes a small increase in the corrected 
QT interval (QTc). [28229] [28230] [28231] [29758] [34389] [65157] [65170]
Tetracaine: (Moderate) Coadministration of tetracaine with oxidizing agents, such as chloroquine, 
may increase the risk of developing methemoglobinemia. Monitor patients closely for signs and 
symptoms of methemoglobinemia if coadministration is necessary. If methemoglobinemia occurs 
or is suspected, discontinue tetracaine and any other oxidizing agents. Depending on the severity 
of symptoms, patients may respond to supportive care; more severe symptoms may require 
treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. [31353]
Thiazolidinediones: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including the thiazolidinediones, are coadministered. A 
decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been 
reported in patients treated concomitantly with chloroquine and an antidiabetic agent. [29758]
Thioridazine: (Severe) Coadministration of chloroquine with thioridazine is contraindicated due to 
the increased risk of QT prolongation. Chloroquine is associated with an increased risk of QT 
prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher 
chloroquine doses. Thioridazine is associated with a well-established risk of QT prolongation and 
TdP. [28225] [28229] [28230] [28231] [28293] [29758] [65170]
Tiotropium; Olodaterol: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Tolazamide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Tolbutamide: (Major) Careful monitoring of blood glucose is recommended when chloroquine and 
antidiabetic agents, including the sulfonylureas, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Tolterodine: (Major) Avoid coadministration of chloroquine with tolterodine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Tolterodine has been associated with dose-dependent prolongation 
of the QT interval, especially in poor CYP2D6 metabolizers. [28229] [28230] [28231] [29758] [31112]
[65157] [65170]
Toremifene: (Major) Avoid coadministration of chloroquine with toremifene due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Toremifene has been shown to prolong the QTc interval in a dose- 
and concentration-related manner. [28229] [28230] [28231] [28822] [29758] [65157] [65170]
Trametinib: (Moderate) Concurrent use of chloroquine and trametinib is not recommended as 
there is an increased risk of retinal toxicity. [29758] [60372]
Trazodone: (Major) Avoid coadministration of chloroquine with trazodone due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Trazodone can prolong the QT/QTc interval at therapeutic doses. 
In addition, there are postmarketing reports of TdP. [28229] [28230] [28231] [29758] [38831] [63609]
[65157] [65170]
Tricyclic antidepressants: (Major) Avoid coadministration of chloroquine with tricyclic 
antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, 
obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent 
ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de 
pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. TCAs share 
pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT 
interval, particularly in overdose or with higher-dose prescription therapy (elevated serum 
concentrations). [28225] [28229] [28230] [28231] [28415] [28416] [29758] [65157] [65170]
Trifluoperazine: (Major) Avoid coadministration of chloroquine with trifluoperazine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Trifluoperazine is associated with a possible risk for QT 
prolongation. [28229] [28230] [28231] [28415] [29758] [65157] [65170]
Trimipramine: (Major) Avoid coadministration of chloroquine with tricyclic antidepressants 
(TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. TCAs share pharmacologic properties 
similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in 
overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28229]
[28230] [28231] [28415] [28416] [29758] [65157] [65170]
Triptorelin: (Major) Avoid coadministration of chloroquine with triptorelin due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Androgen deprivation therapy (i.e., triptorelin) may prolong the 
QT interval. [28229] [28230] [28231] [29758] [45411] [65157] [65170]
Ultralente Insulin: (Major) Careful monitoring of blood glucose is recommended when 
chloroquine and antidiabetic agents, including insulin, are coadministered. A decreased dose of the 
antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated 
concomitantly with chloroquine and an antidiabetic agent. [29758]
Umeclidinium; Vilanterol: (Major) Avoid coadministration of chloroquine with long-acting beta-
agonists due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG 
at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, 
avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is 
associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT 
prolongation is increased with higher chloroquine doses. Beta-agonists may be associated with 
adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when 
associated with hypokalemia, or when used with other drugs known to prolong the QT interval. 
This risk may be more clinically significant with long-acting beta-agonists (LABAs) as compared 
to short-acting beta-agonists.. [28229] [29758] [41231] [44026] [44063] [44979] [59321] [65157] [65170]
Vandetanib: (Major) Avoid coadministration of chloroquine with vandetanib due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. An interruption of vandetanib therapy or 
dose reduction may be necessary for QT prolongation. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Vandetanib can prolong the QT interval in a concentration-
dependent manner; TdP and sudden death have been reported in patients receiving vandetanib. 
[28229] [28230] [28231] [29758] [43901] [65157] [65170]
Vardenafil: (Major) Avoid coadministration of chloroquine with vardenafil due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Vardenafil is associated with QT prolongation. Both therapeutic 
and supratherapeutic doses of vardenafil produce an increase in QTc interval. [28216] [28229]
[29758] [41124] [59321] [65157] [65170]
Vemurafenib: (Major) Avoid coadministration of chloroquine with vemurafenib due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Vemurafenib has also been associated with QT 
prolongation. [28229] [28230] [28231] [29758] [45335] [59321] [65157] [65170]
Venlafaxine: (Major) Avoid coadministration of chloroquine with venlafaxine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Venlafaxine administration is associated with a possible risk of QT 
prolongation; TdP has been reported with postmarketing use. [28229] [28230] [28231] [29758] [33715]
[65157] [65170]
Vigabatrin: (Major) Vigabatrin should not be used with chloroquine due to potential retinal 
toxicity associated with both drugs, unless the benefits of treatment clearly outweigh the risks. 
[29758] [36250]
Voriconazole: (Major) Avoid coadministration of chloroquine with voriconazole due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with 
an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is 
increased with higher chloroquine doses. Voriconazole has been associated with QT prolongation 
and rare cases of TdP. [28158] [28229] [28230] [28231] [29758] [65157] [65170]
Vorinostat: (Major) Avoid coadministration of chloroquine with vorinostat due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Vorinostat therapy is also associated with a risk of QT 
prolongation. [28229] [28230] [28231] [29758] [32789] [65157] [65170]
Ziprasidone: (Major) Avoid coadministration of chloroquine with ziprasidone due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial 
QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased 
risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased 
with higher chloroquine doses. Clinical trial data indicate that ziprasidone causes QT 
prolongation; there are postmarketing reports of TdP in patients with multiple confounding 
factors. [28229] [28230] [28231] [28233] [29758] [65157] [65170]
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34389 – Xenazine (tetrabenazine) package insert. Deerfield, IL: Lundbeck, Inc.; 2017 Sep.
35401 – Coartem (artemether; lumefantrine) package insert. East Hanover, NJ: Novartis 
Pharmaceuticals Corporation; 2019 Aug.
36101 – Multaq (dronedarone) package insert. Bridgewater, NJ: Sanofi-aventis; 2014 Mar.
36146 – Fanapt (iloperidone) package insert. Rockville, MD: Vanda Pharmaceuticals, Inc.; 2017 
Mar.
36250 – Sabril (vigabatrin) tablet/powder for oral solution package insert. Deerfield, IL: Lundbeck 
Inc.; 2020 Jan.
36343 – Saphris (asenapine) package insert. St. Loius, MO: Forest Pharmaceuticals, Inc.; 2017 
Mar.
36615 – Vibativ (telavancin) package insert. Nashville, TN: Cumberland Pharmaceuticals Inc.; 
2020 Feb.
37098 – Votrient (pazopanib) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2011 
Oct.
37292 – Istodax (romidepsin) package insert. Bedford, OH: Ben Venue Laboratories, Inc.; 2018 
Nov.
38831 – Oleptro (trazodone hydrochloride) extended-release tablets package insert. Dublin, 
Ireland: Labopharm Europe Limited; 2014 Jul.
40233 – Sporanox (itraconazole) oral solution package insert. Titusville, NJ: Janssen 
Pharmaceuticals, Inc.; 2019 Mar.
40848 – Imovax Rabies (rabies vaccine) package insert. Swiftwater, PA: Sanofi-Pasteur Inc.; 2019 
Oct.
40849 – RabAvert (rabies vaccine) package insert. Emeryville, CA: Novartis Vaccines and 
Diagnostics, Inc.; 2018 August.
40936 – Invega Sustenna (paliperidone palmitate injectable suspension) package insert. Titusville, 
NJ: Janssen Pharmaceuticals, Inc.; 2019 Jan.
40942 – Remeron and RemeronSolTabs (mirtazapine tablets and ODT tablets) package insert. 
Roseland, NJ: Organon USA, Inc.; 2020 Mar.
41124 – Staxyn (vardenafil orally disintegrating tablets) package insert. Research Triangle Park, 
NC: GlaxoSmithKline; 2017 Aug.
41231 – Foradil inhalation powder (formoterol fumarate) package insert. Kenilworth, NJ: 
Schering Corporation; 2012 Nov.
41235 – Butrans (buprenorphine transdermal system) package insert. Stamford, CT: Purdue 
Pharma L.P.; 2019 Oct.
41806 – Plaquenil (hydroxychloroquine) package insert. St. Michael, Barbados: Concordia 
Pharmaceuticals, Inc.; 2017 Jan.
41830 – Corvert (ibutilide) package insert. New York, NY: Pharmacia and Upjohn Company; 
2016 Aug.
41958 – Eloxatin (oxaliplatin) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC; 2020 
April.
41984 – Primaquine phosphate package insert. Bridgewater, NJ: Sanofi-aventis; 2017 Jun.
42039 – Quelicin (succinylcholine) package insert. Lake Forest, IL: Hospira, Inc.; 2018 Jul.
42121 – Pradaxa (dabigatran) package insert. Ridgefield, CT: Boehringer Ingelheim 
Pharmaceuticals, Inc.; 2019 Nov.
42280 – Nuedexta (dextromethorphan hydrobromide; quinidine sulfate capsule) package insert. 
Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; 2019 Jun.
42449 – Halaven (eribulin mesylate) injection package insert. Woodcliffe Lake, NJ: Eisai Inc.; 
2016 Oct.
42844 – FDA Drug Safety Communication: Abnormal heart rhythms associated with use of 
Anzemet (dolasetron mesylate). Retrieved December 17, 2010. Available on the World Wide Web 
at: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm.
42845 – Abilify (aripiprazole) tablets, discmelt orally-disintegrating tablets, oral solution, and 
intramuscular injection package insert. Tokyo, Japan: Otsuka America Pharmaceutical, Inc.; 2020 
Feb.
43065 – Chlorpromazine package insert. Princeton, NJ: Sandoz Inc; 2019 Dec.
43258 – Eryped (erythromycin ethylsuccinate) package insert. Atlanta, GA: Arbor 
Pharmaceuticals, INC.; 2018 Apr.
43383 – Xylocaine (lidocaine injection), Xylocaine (lidocaine and epinephrine injection) package 
insert. Lake Zurich, IL: Fresenius Kabi; 2018 Nov.
43411 – Cipro (ciprofloxacin tablet; suspension) package insert. Wayne, NJ: Bayer HealthCare 
Pharmaceuticals Inc.; 2020 Mar.
43463 – Orap (pimozide) package insert. Sellersville, PA: Teva Pharmaceuticals USA; 2014 Mar.
43800 – Lupron Depot (leuprolide acetate for depot suspension) package insert. North Chicago, 
IL: AbbVie Inc; 2017 July.
43901 – Caprelsa (vandetanib) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 
2018 Oct.
43974 – Zithromax (azithromycin injection) package insert. New York, NY: Pfizer Inc.; 2019 Apr.
44026 – Advair HFA (fluticasone propionate; salmeterol inhalation aerosol) package insert. 
Research Triangle Park, NC: GlaxoSmithKline; 2019 Jan.
44058 – Prozac Weekly (fluoxetine hydrochloride delayed-release capsules) package insert. 
Indianapolis, IN: Lilly USA, LLC; 2017 Mar.
44059 – Sarafem (fluoxetine hydrochloride) package insert. Irvine, CA: Allergan USA, Inc; 2017 
Jan.
44063 – Advair Diskus (fluticasone propionate; salmeterol inhalation powder) package insert. 
Research Triangle Park, NC: GlaxoSmithKline; 2019 Jan.
44376 – Edurant (rilpivirine) package insert. Titusville, NJ: Janssen Therapeutics; 2019 May.
44406 – Fosrenol (lanthanum carbonate chewable tablets and oral powder) package insert. 
Lexington, MA: Shire US Inc.; 2018 Nov.
44800 – Potiga (ezogabine) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2016 
May.
44979 – Arcapta Neohaler (indacaterol inhalation powder) package insert. East Hanover, NJ: 
Novartis Pharmaceuticals Corporation; 2019 May.
45335 – Zelboraf (vemurafenib) tablet package insert. South San Francisco, CA: Genentech USA, 
Inc.; 2017 Nov.
45411 – Trelstar (triptorelin pamoate for injectable suspension) package insert. Parsipanny, NJ: 
Watson Pharma, Inc; 2018 Dec.
45458 – Xalkori (crizotinib) package insert. New York, NY: Pfizer Labs; 2019 June.
46655 – Ciprofloxacin injection (vials) package insert. Lake Forest, IL: Hospira, Inc. 2020 Jan.
46869 – Firmagon (degarelix) package insert. Parsippany, NJ: Ferring Pharmaceuticals Inc.; 2020 
Dec.
47129 – Hydroxyzine hydrochloride injection package insert. Shirley, NY: American Regent, Inc.; 
2016 Oct.
47221 – Propulsid (cisapride) package insert. Titusville, NJ; Janssen Pharmaceutica; 2006 Oct. 
NOTE: As of May 2000; Propulsid has only been available in the United States via an 
investigational limited access program to ensure proper patient screening and prescribing.
47357 – Quinidine gluconate extended release tablet package insert. Richmond, VA: Richmond 
Pharmaceuticals, Inc.; 2011 Jan.
47391 – Intron A (interferon alfa-2b, recombinant) package insert. Whitehouse Station, NJ: Merck 
& Co, Inc.; 2018 May.
48697 – Korlym (mifepristone) tablet package insert. Menlo Park, CA: Corcept Therapeutics 
Incorporated; 2017 May.
49951 – Ventolin HFA (albuterol sulfate) Inhalation Aerosol package insert. Research Triangle 
Park, NC: GlaxoSmithKline; 2014 Dec.
50507 – Luvox CR (fluvoxamine maleate extended-release capsules) package insert. Palo Alto, 
CA: Jazz Pharmaceuticals, Inc.; 2017 Jan.
51070 – Tambocor (flecainide) package insert. Scottsdale, AZ: Medicis, The Dermatology 
Company; 2011 Dec.
51289 – Inapsine (droperidol) package insert. Lake Forest, IL: Akorn, Inc.; 2011 Nov.
51740 – Maprotiline HCl tablet package insert. Morgantown WV: Mylan Pharmaceuticals Inc; 
2014 Dec.
51793 – Xopenex (levalbuterol) inhalation solution package insert. Lake Forest, IL: Akorn, Inc.; 
2019 Jan.
52330 – Naropin (ropivacaine) injection package insert. Lake Zurich, IL: Fresenius Kabi USA, 
LLC; 2018 Nov.
52331 – Marcaine (bupivacaine) injection package insert. Lake Forest, IL: Hospira, Inc.; 2018 
Nov.
52603 – Iclusig (ponatinib) tablet package insert. Cambridge, MA: Takeda Pharmaceuticals 
Company Limited; 2020 Jan.
52746 – Sirturo (bedaquiline) tablet package insert. Titusville, NJ: Janssen Therapeutics; 2020 
Jan.
53394 – Abilify Maintena (aripiprazole) extended-release intramuscular injection package insert. 
Rockville, MD:Otsuka America Pharmaceutical, Inc.; 2020 Feb.
55401 – Astagraf XL (tacrolimus extended-release capsules) package insert. Northbrook, IL: 
Astellas Pharma US, Inc.; 2018 Nov.
55578 – Owczuk R, Twardowski P, Dylczyk-Sommer A, et al. Influence of promethazine on 
cardiac repolarization: a double-blind, midazolam-controlled study. Anaesthesia 2009;64:609-614.
57094 – Zykadia (ceritinib) package insert. Indianapolis, IN: Novartis; 2019 March.
57377 – Altin C, Kanyilmaz S, Baysal S, et al. QT interval prolongation due to metronidazole 
administration. Anadolu Kardiyol Derg 2011;11:46-9.
57378 – Cohen O, Saar N, Swartzon M, et al. First report of metronidazole-induced QT interval 
prolongation. Int J Antimicrob Agents 2008;31:180-81.
57441 – Iribarren C, Round AD, Peng JA, et al. Validation of a population-based method to assess 
drug-induced alterations in QT interval: a self-controlled crossover study. Pharmacoepidemiol 
Drug Saf 2013;22;1222-32.
57803 – Cerdelga (eliglustat) capsules. Waterford, Ireland: Genzyme Ireland, Ltd.;2018 Sept.
58685 – Savaysa (edoxaban) package insert. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2019 Aug.
58766 – Tasigna (nilotinib) capsules package insert. East Hanover, NJ: Novartis Pharmaceuticals 
Corporation; 2019 Sept.
58782 – Lenvima (lenvatinib) package insert. Woodcliff Lake, NJ:Eisai Inc; 2020 Feb.
58821 – Farydak (panobinostat) capsules package insert. East Hanover, NJ: Novartis 
Pharmaceuticals Corporation; 2016 June.
59321 – CredibleMeds. QT drug lists. Available on the World Wide Web at 
http://www.crediblemeds.org.
59322 – Howes LG. Cardiovascular effects of drugs used to treat alzheimer's disease. Drug Saf. 
2014;37:391–395.
59809 – Mamiya K, Sadanaga T, Sekita A, et al. Lithium concentration correlates with QTc in 
patients with psychosis. J Electrocardiol 2005;38:148-51.
59810 – van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with 
corrected QT interval prolongation. J Clin Psychopharmacol 2009;29:9-15.
59811 – Altinbas K, Guloksuz S, Caglar IM, et al. Electrocardiography changes in bipolar patients 
during long-term lithium monotherapy. Gen Hosp Psychiatry 2014;36:694-7.
60196 – Aristada (aripiprazole lauroxil) extended-release intramuscular suspension package insert. 
Waltham, MA: Alkermes, Inc.; 2017 Jun.
60270 – Belbuca (buprenorphine) buccal film package insert. BioDeliviery Sciences International, 
Inc.: Raleigh, NC; 2019 Oct.
60281 – Cotellic (cobimetinib) tablets package insert. San Francisco, CA: Genentech USA, Inc; 
2016 June.
60297 – Tagrisso (osimertinib) tablet package insert. Wilmington, DE: AstraZeneca 
Pharmaceuticals LP; 2018 Aug.
60372 – Mekinist (trametinib) tablets package insert. East Hanover, NJ: Novartis Pharmaceuticals 
Corporation; 2020 Apr.
60497 – Envarsus XR (tacrolimus) extended-release tablets. Cary, NC: Veloxis Pharmaceuticals, 
Inc.; 2018 Dec.
60612 – Aczone (dapsone gel 7.5%) package insert. Exton, PA: Almirall, LLC; 2019 Sept.
60686 – Fluconazole injection package insert. New York, NY: Pfizer; 2014 Jun.
60748 – Nuplazid (pimavanserin) package insert. San Diego, CA: Acadia; 2019 Sep.
60864 – US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA 
warns about serious heart problems with high doses of the antidiarrheal medicine loperamide 
(Imodium), including from abuse and misuse. Retrieved June 7, 2016. Available on the World 
Wide Web at: http://www.fda.gov/Drugs/DrugSafety/ucm504617.htm?
source=govdelivery&utm_medium=email&utm_source=govdelivery
60957 – Avloclor (chloroquine phosphate) tablets. Summary of product characteristics. European 
package labeling. Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB United 
Kingdom: Alliance Pharmaceuticals; 2016 Jun. Accessed: July 9 , 2016. Available at: 
http://www.medicines.org.uk/emc/medicine/2272
61195 – Levofloxacin injection package insert. North Brunswick, NJ: Claris Injectables Ltd.; 2018 
Jun.
61470 – Vistaril (hydroxyzine pamoate) package insert. New York, NY: Pfizer Labs; 2016 Nov.
61759 – Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-
dose cimetidine. J Clin Pharmacol 1987;27:813-16.
61760 – Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of 
rheumatic diseases. Lupus 1996;5(S1):S11-15.
61761 – Ali HM. Reduced ampicillin bioavailability following oral coadministration with 
chloroquine. J Antimicrob Chemother 1985;15:781-4.
61816 – Kisqali (ribociclib) tablets package insert. East Hanover, NJ: Novartis Pharmaceuticals 
Corporation; 2020 Jan.
61845 – Austedo (deutetrabenazine) tablets package insert. North Wales, PA: Teva 
Pharmaceuticals USA, Inc.; 2019 Jul.
61872 – Slovacek L, Ansorgova V, Macingova Z, et al. Tamoxifen-induced QT interval 
prolongation. J Clin Pharm Ther. 2008;33(4):453-5.
61906 – Rydapt (midostaurin) capsule package insert. East Hanover,NJ: Novartis Pharmaceuticals 
Corporation; 2020 Mar.
62037 – Bevyxxa (betrixaban) capsules package insert. South San Francisco, Ca: Portola 
Pharmaceuticals, Inc.; 2019 Jul.
62245 – Besponsa (inotuzumab ozogamicin) injection package insert. Philadelphia, PA: Wyeth 
Pharmaceuticals Inc; 2017 Aug.
62292 – Mylotarg (gemtuzumab ozogamicin) injection package insert. Philadelphia, PA: Pfizer 
Inc.; 2020 Feb.
62723 – Macrilen (macimorelin) package insert. Frankfurt am Main, Germany: Aeterna Zentaris 
GmbH; 2018 Jan.
63161 – Lucemyra (lofexidine) tablets package insert. Louisville, KY: US WorldMeds, LLC; 2018 
May.
63317 – Braftovi (encorafenib) capsules package insert. Boulder, CO: Array BioPharma Inc.; 2020 
April.
63589 – Soltamox (tamoxifen) oral solution package insert. Raleigh, NC: Midatech Pharma US 
Inc.; 2019 April.
63609 – Desyrel (trazodone) package insert. Locust Valley, NY: Pragma Pharmaceuticals, LLC.; 
2017 June.
63729 – Levofloxacin premix injection package insert. Lake Forest, IL: Hospira; 2019 Jan.
63777 – Daurismo (glasdegib) tablets package insert. New York, NY: Pfizer Labs; 2020 Mar.
63787 – Xospata (gilteritinib) tablets package insert. Northbrook, IL: Astellas Pharma US, Inc.; 
2019 May.
63821 – Tolsura (itraconazole) capsules package insert. Greenville, NC: Mayne Pharma; 2018 
Dec.
63936 – Lamprene (clofazimine) package insert. East Hanover, NJ: Novartis Pharmaceuticals 
Corporation; 2019 Jan.
64031 – Mayzent (siponimod) tablets package insert. East Hanover, NJ: Novartis Pharmaceutical 
Corporation; 2019 Mar.
64391 – Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake 
inhibitor-associated QTc prolongation. J Clin Psychiatry 2014;75:e441-e449.
64392 – Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression 
in patients with acute MI or unstable angina. JAMA 2002;288:701-709.
64394 – O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for 
depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against 
Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010;56:692-699.
64396 – Beach SR, Celano CM, Sugrue AM, et al. QT prolongation, torsades de pointes, and 
psychotropic medications: a 5-year update. Psychosomatics 2018;59:105-122.
64562 – Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, 
LLC; 2019 Aug.
64567 – Rozlytrek (entrectinib) package insert. South San Francisco, CA: Genentech Inc.; 2019 
Aug.
64576 – Xenleta (lefamulin) package insert. Dublin, Ireland: Nabriva Therapeutics US, Inc.; 2019 
Aug.
64969 – Bynfezia Pen (octreotide acetate) injection package insert. Cranbury, NJ: Sun 
Pharmaceutical Industries, Inc; 2020 Jan.
65098 – Isturisa (osilodrostat) tablet package insert. Lebanon, NJ: Recordati Rare Disease, Inc.; 
2020 Mar.
65157 – CredibleMeds. COVID-19 experimental therapies and TdP risk. Available on the World 
Wide Web at http://https://crediblemeds.org/blog/covid-19-experimental-therapies-and-tdp-risk. 
Accessed March 23, 2020.
65170 – Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for 
navigating and circumventing the QTc prolonging and torsadogenic potential of possible 
pharmacotherapies for COVID-19 [published online ahead of print, March 25, 2020]. Mayo Clin 
Proc 2020;95.
65210 – University of Liverpool. COVID-19 Drug Interactions. Retrived April 6, 2020. Available 
on the World Wide Web at https://www.covid19-druginteractions.org/.
65237 – Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-
AM fluorometry screening assay. Anti-Cancer Drugs 1996;7:568-578.
65239 – Projean D, Baune B, Farinotti R, et al. In vitro metabolism of chloroquine: Identification 
of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine 
formation. Drug Metab Dispos 2003;31:748-754.
Monitoring Parameters
• blood glucose
• CBC
• ECG
• glucose-6-phosphate dehydrogenase (G6PD) activity
• ophthalmologic exam
IV Compatibility of Chloroquine with:
Legend
 = Compatible
 = Incompatible
 = Results uncertain, variable or dependent on conditions
ND = No Data Available
From Trissel's 2™ Clinical Pharmaceutics Database 
Admixture Syringe Y-Site Administration For Dilution
Normal saline- Sodium chloride 0.9% ND ND ND 
Promethazine hydrochloride ND ND 
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US Drug Names
• Aralen
Global Drug names
Argentina
• Nivaquine - (Sanofi-Aventis)
Australia
• Chlorquin - (Aspen)
• Nivaquine - (Rhone-Poulenc Rorer)
Austria
• Resochin - (Bayer)
Belgium
• Nivaquine - (Sanofi)
Brazil
• Clopirim - (Quimioterapica)
• Diclokin - (Kinder)
• Difosquin - (Vitamed)
• Palux - (Biolab Sanus)
• Quinacris - (Cristalia)
Canada
• Aralen - (Sanofi Synthelabo)
Czech Republic
• Delagil - (ICN)
Denmark
• Malarex - (Actavis)
Finland
• Heliopar - (Orion)
France
• Nivaquine - (Sanofi-Aventis)
• Nopalu - (Pharmacie Centrale des Armees)
• Savarine - (AstraZeneca)
Germany
• Arthrabas - (Tosse)
• Resochin - (Bayer)
• Weimerquin - (Biokanol)
Greece
• Avloclor - (IFET)
• Demoquine - (Demo)
• Savarine - (IFET (ΙΦΕΤ))
Hong Kong
• Chlorocin - (Deltapharm)
• Chlorquin - (Fisons)
• Syncoquin - (Synco)
Hungary
• Delagil - (PharmaSwiss)
India
• Bitaquine - (Bombay Tablet)
• Cadiquin - (Zydus)
• Chlorolex - (Lexica)
• Clokit - (Indoco)
• Cloquin - (Indoco)
• C-Quin - (Ikon)
• Emquin - (Merck)
• E-Vivax - (Themis Medicare)
• Idiquin - (Indian Drugs)
• Ingaquine - (Inga)
• Jagquin - (Jagsonpal)
• La-Quin - (Stadmed)
• Lariago - (Ipca)
• Larover - (Aglowmed)
• Malaquin - (PC India)
• Maliago - (Cipla)
• Maligon - (Unijules)
• Malswift - (Ind-Swift)
• Melubrin - (Ranbaxy)
• Neoquine - (Neon)
• Nivaquine-P - (Piramal)
• Paraquin - (Shreya)
• Resochin - (Bayer)
Indonesia
• Avloclor - (AstraZeneca)
• Malarex - (Actavis)
• Mexaquin - (Konimex)
• Resochin - (Bayer)
• Riboquin - (Dexa)
Ireland
• Avloclor - (AstraZeneca)
• Nivaquine - (Rhone-Poulenc Rorer)
Israel
• Aralen - (Sanofi Winthrop)
• Avloclor - (Zeneca)
Italy
• Dichinalex - (Recordati)
Mexico
• Aralen - (Sanofi-Aventis)
• Klorokin - (Zerboni)
• Maclorex - (Alpharma)
• Paluken - (Kener)
Netherlands
• Nivaquine - (Sanofi-Aventis)
New Zealand
• Chlorquin - (Healthcare Logistics)
• Nivaquine - (Aventis)
Philippines
• Aralen - (Sanofi Synthelabo)
• Chlorofoz - (Am-Europharma)
• Chloromax - (Oboi)
• Clorkin - (Doctors)
Poland
• Arechin - (Polfa Pabianice)
Portugal
• Resochina - (BayHealth)
Russian Federation
• Delagil - (ICN)
Singapore
• Avloclor - (AstraZeneca)
• Malarex - (Danone Dumex)
South Africa
• Anoclor - (Rolab)
• Daraclor - (Glaxo Wellcome)
• Daramal - (GSK)
• Daramal-Paludrine - (Zeneca)
• Mirquin - (Mirren)
• Nivaquine - (Winthrop)
• Plasmoquine - (Medchem)
• Promal - (Propan)
Spain
• Cidanchin - (Cidan)
• Resochin - (Kern)
Switzerland
• Chlorochin - (Streuli)
• Nivaquine - (Sanofi-Aventis)
• Pharmaquine - (Pharma Plus)
• Resochine - (Bayer)
Thailand
• Chewoquine - (Chew)
• Diroquine - (Atlantic)
• Genocin - (General Drugs)
• Malacin - (ANB)
• Maliaquine - (Sriprasit)
• Nitaquin - (Utopian)
• P-Roquine - (PP Lab)
• Sinmoquin - (SSP)
Turkey
• Kutlu - (Keymen)
Ukraine
• Delagil - (Meda)
United Kingdom
• Avloclor - (Alliance)
• Malarivon - (Wallace Mfg Chem.)
• Malaviron - (Wallace Mfg Chem.)
• Nivaquine - (Sanofi-Aventis)
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